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Business leaders who fail to implement innovative technology solutions in their 
companies face economic distress in these organizations. Guided by the task technology 
fit model as the conceptual framework, the purpose of this qualitative single case study 
was to explore strategies used by pharmacovigilance (PV) systems leaders to implement 
innovative technology solutions. The participants were 4 PV systems managers working 
in a pharmaceutical company in the Boston area of Massachusetts, United States, who 
used successful strategies to implement innovative technology solutions to automate 
adverse events case processing. Data were collected using semistructured interviews and 
company documents.  The collected data were analyzed using Yin’s 5-step data analysis, 
which included compiling, disassembling, reassembling, interpreting data, and 
concluding the findings. Three key themes emerged: automation solution selection and 
implementation strategies, business operation model changes, and communication and 
training strategies. The key recommendation is for PV leaders to implement automation 
solutions and redirect the savings from PV operations in terms of cost and workforce 
tasks toward investing in the actual PV tasks such as benefit-risk assessments of products. 
The implications for positive social change include the potential to identify strategies to 
improve patient outcomes and assist in making pharmaceutical medicines more 
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Section 1: Foundation of the Study  
The goal of pharmacovigilance (PV) is to protect patients from unnecessary harm. 
When a medicine is marketed, the identification and monitoring of adverse events (AEs) 
and reactions is a part of a post-marketing safety surveillance program as required by 
federal regulations (Kothari, Shah, & Patel, 2018; Tan et al., 2016). Health regulatory 
agencies have regulations to ensure that drug products are safe for human consumption. 
Companies that are licensed marketing authorization holders are required by regulation to 
perform active drug safety surveillance and monitor the safety profiles of the products 
during the entire marketing lifecycle (Basile, Yahi, & Tatonetti, 2019). Companies use 
safety databases and reporting software to process and report AEs to health authorities 
around the world (Lewis & McCullum, 2019). Companies can use innovative information 
technology solutions based on artificial intelligence and robotics to detect, process, and 
report AEs, thereby adopting automation (Beninger, 2018; Donzanti, 2018). Companies 
can adopt an automation-enabled digital PV path for drug safety surveillance and redirect 
the savings from PV operations toward investing in the actual PV tasks like benefit-risk 
assessments of products, thereby making the products more efficacious and safer for 
human use. 
Background of the Problem 
The safety of medicines is a global responsibility. A drug product or medicine 
will gain marketing authorization after a regulatory agency conducts comprehensive 
reviews of the drug product to evaluate the benefits and risks (Schurer, Bam, & de Kock, 
2017). When the officials of the agency find a favorable benefit-risk balance, they 
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approve the drug product to be marketed within the jurisdiction of the relevant agency 
(Kothari et al., 2018). When the product is marketed and consumed by a large population, 
adverse reactions or side effects may occur (Pitts, Louet, Moride, & Conti, 2016). When 
a product is reported to have caused serious AEs, national authorities analyze the reports 
of the product and weigh the risks and benefits. They then decide on a course of action, 
which may include issuing an alert or, in extreme cases, taking the product off the market 
(McNaughton, Huet, & Shakir, 2014). 
The goal of PV is to protect patients from unnecessary harm. Unsafe healthcare 
causes harm and leads to other forms of collateral damage such as loss of trust in the 
system and loss of reputation and credibility in health services (World Health 
Organization, 2017). The occurrence of AE is one of the top 10 causes of death and 
disability across the world (World Health Organization, 2019a). Officials of the World 
Health Organization reported that 134 million adverse events occur each year in 
hospitals, contributing to 2.6 million deaths annually due to unsafe care (World Health 
Organization, 2019c).  
Biomedical informatics including artificial intelligence (AI) and robotics-based 
solutions can accelerate efficiencies and can be used to identify and process AEs faster 
and contribute to reduction of costs (Beninger, 2018; Donzanti, 2018). Despite multiple 
successful experiments, not many managers in pharmaceutical companies have developed 




Business leaders who fail to implement innovative technology solutions in their 
companies face economic distress in these organizations (Bal & Erkan, 2019). Failure to 
implement innovative technology solutions result in high pharmacovigilance (PV) 
operational costs related to the 2.2 million adverse events (AEs) documented by the U.S. 
Food & Drug Administration (2019) that could cost pharmaceutical companies $900 
million for drug recalls (Hall, Stewart, Chang, & Freeman, 2016). The general business 
problem is that PV systems managers may experience high operational costs for AE 
detection and reporting leading to poor financial performance. The specific business 
problem is that some PV systems managers in the pharmaceutical industry lack the 
strategies to implement innovative technology solutions to automate AE case processing. 
Purpose Statement 
The purpose of this qualitative single case study was to explore the strategies that 
PV systems managers in the pharmaceutical industry use to implement innovative 
technology solutions to automate AE case processing. The target population consisted of 
four PV systems managers working in a pharmaceutical company located in the Boston 
area of Massachusetts, United States, who had used successful strategies to implement 
innovative technology solutions to automate AE case processing. The implications for 
positive social change include the potential to improve patient safety by identifying 
successful strategies that PV systems managers can use or adapt to implement innovative 
technology solutions to automate AE case processing. 
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Nature of the Study 
Qualitative studies are based on interpretive philosophy. Using an inductive 
approach, researchers use a smaller sample of participants’ data to develop rich data and 
thick descriptions through a variety of methods for data collection to identify patterns 
associated with phenomena (Fusch, Fusch, & Ness, 2018; Saunders, Lewis, & Thornhill, 
2015). In quantitative and mixed methods studies, researchers use quantitative measures 
and inferential statistics to examine relationships among variables (Saunders et al., 2015). 
Since not many company managers have implemented innovative technology like AI and 
robotics-based solutions for PV (Beninger & Ibara, 2016), I focused on a select group of 
managers who had successfully used strategies to implement innovative technology 
solutions to automate AE case processing. Therefore, because of the need to use 
qualitative data collection procedures like interviews and documentation reviews, a 
qualitative method was more appropriate than quantitative or mixed methods. 
Qualitative case studies are flexible in nature, focusing on a phenomenon, and 
evolve over the course of the study (Yin, 2018). Using a case study strategy enables 
researchers to perform in-depth inquiry into a topic to generate insights in a real-life context 
experiences (Saunders et al., 2015; Yin, 2018). Using multiple case study design, researchers 
can collect and analyze data to gather perspectives and identify patterns and themes 
concerning a specific situation across multiple cases (Yin, 2018). Using ethnography and 
phenomenological study designs, researchers focus on people, culture, and phenomena 
(Saunders et al., 2015). Because I explored successful innovative technology implementation 
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strategies used by PV systems managers in a pharmaceutical company, a single case study 
design was more appropriate for this study than a phenomenological or ethnographic design. 
Research Question 
The primary research question for this study was: What strategies do PV systems 
managers use to implement innovative technology solutions to automate AE case 
processing? 
Interview Questions  
1. What strategies did you use to identify automation solutions for AE case 
processing?   
2. What strategies did you use for implementing the identified automation solution?  
3. What, if any, kinds of operational changes did the automation solution require to 
your PV business operations model? 
4. What communication strategies were used to manage regulatory obligations and 
employee’s expectations to enable employee’s adoption of the automation 
solution? 
5. What key difficulties did your organization face when implementing the 
automation technology solution? 
6. How did your organization overcome the key difficulties to implementing 
automation technology solution? 
7. How did your organization assess the implementation strategies’ effectiveness? 
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8. What additional information can you add about the development and 
implementation of the strategies your organization used for automating AE case 
processing? 
Conceptual Framework 
The conceptual framework that I selected for my doctoral study was based on the 
information systems theory’s task-technology fit (TTF) model. The TTF model focuses 
on the degree to which systems characteristics match user task needs. Goodhue (1995) 
proposed the TTF model to evaluate and measure success of information systems and 
posited that a high task-technology fit will positively impact the performance. Goodhue 
and Thompson (1995) further empirically tested the link between information technology 
and individual performance and asserted that the utilization of technology and the 
technology itself must be a good fit for the tasks it supports. TTF links the task 
requirements, individual abilities, and the functionality of technology. More recent 
researchers have improved the TTF model by incorporating additional characteristics and 
constructs or by integrating other theories such as the appropriation theories (Park, 2019). 
I compared the expected results from the TTF model with the actual results from my 
study to understand the study’s findings. 
Operational Definitions 
Adverse events or reactions: Adverse events or reactions are unexpected harm 
caused by the normal use of medication at the normal dosage (Karimi, Wang, Metke-
Jimenez, Gaire, & Paris, 2015). 
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Adverse event reporting: Adverse event reporting refers to the activities that 
marketing authorization holders perform to collect, and report AE cases reported by 
patients as required by a 2012 PV legislation (Kothari et al., 2018). 
Digitalization: Digitalization involves using digitized data to make decisions and 
generate change (Gobble, 2018). 
Healthcare information technology: Healthcare information technology is the 
application of computers for the storage, retrieval, sharing, and use of health care 
information, data, and knowledge for communication and decision making (Alotaibi & 
Federico, 2017).  
Pharmacovigilance: PV is studying the safety and effectiveness of drugs 
including the activities relating to detection, assessment, understanding, and prevention 
of the AE associated with the use of drugs (World Health Organization, 2019b). 
Assumptions, Limitations, and Delimitations 
Assumptions 
Assumptions are unverified beliefs pertaining to a study (Locke, Spirduso, & 
Silverman, 2014). I made the following assumptions in this study: (a) the participants 
provided honest, truthful responses to the interview questions, (b) the participants had 
relevant information and experiences, (c) the responses provided by the participants 
assisted in understanding the strategies used to implement innovative technology 
solutions to automate AE case processing, and (d) the strategies provided by the 
participants improved efficiencies in processing AEs. Following the conclusion of my 




Limitations are potential weaknesses which are beyond the researcher’s control 
(Singh, 2015). One of the limitations for this study was that the participants were 
employed in one pharmaceutical company. Restricting the study population to one 
company may limit the transferability of the methods used in my study for future 
research. Another limitation was that the member checking was conducted by emails 
since most of the follow-ups occurred during the actual interviews.  
Delimitations 
Delimitations are boundaries intentionally established to narrow the scope of a 
study for the researcher (Holloway & Galvin, 2016). The scope of my study was limited 
to participants from one pharmaceutical company. A purposeful sampling of four 
participants who were associated with the AE case processing automation project was a 
delimitation. Potential participants who did not work for the selected company, though 
eligible, were not a part of this study.  
Significance of the Study 
PV is a study of the safety and effectiveness of drugs including the activities 
relating to detection, assessment, understanding, and prevention of the AEs associated 
with the use of drugs (Beninger & Ibara, 2016; World Health Organization, 2019b). 
Processing of an AE is an expensive resource-intensive process, which includes high risk 
of errors and operational inefficiencies (Ghosh et al., 2020). In 2019, the U.S. Food & 
Drug Administration (2019) received 2.2 million AEs which is a 450% increase since 
2009, which increased the derivative AE-related operational costs for pharmaceutical 
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companies. Biomedical informatics including AI and robotics-based solutions can 
accelerate efficiencies, identify and process AEs faster, and contribute to costs’ reduction 
(Beninger, 2018; Donzanti, 2018). I explored the strategies that PV systems managers in 
the pharmaceutical industry use to implement innovative technology solutions to 
automate AE processing.  
Contribution to Business Practice  
Information technology (IT) offers a wide range of opportunities to organizations 
for automating, informing, and transforming their businesses. The IT-driven approach 
toward business process management enables business process innovation to align with 
industry best practices and emerging IT trends (Rahimi, Moller, & Hvam, 2015). 
Managers must build dynamic capabilities and learning in their organizational processes 
(Čiutienė & Thattakath, 2014), which in combination with business model innovation 
should result in higher value appropriation (Sorescu, 2017). PV technology systems can 
be effective in detecting what may be otherwise invisible to the human eye, increasing 
productivity, and more likely to identify important public health information within large 
data bases (Lu, 2009). Data mining, machine learning, AI, and robotics could result in 
new operating models for PV (Beninger & Ibara, 2016; Lai, 2017), improve efficiencies 
and reduce PV operations costs (Karimi et al., 2015; Lu, 2009; Schmider et al., 2018), 
better allocation of resources, and improve patient outcomes (Lewis & McCallum, 2019). 
Implications for Social Change  
The implications for positive social change include the potential to identify 
strategies to assist in making pharmaceutical medicines safer for human consumption. PV 
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leaders can redirect the savings from PV operations toward investing in the actual PV 
tasks like benefit-risk assessments of products, thereby improving patient outcomes and 
making the products more efficacious and safer for human use. The savings from PV 
operations could also be used to help or assist with community projects that could bring 
about social change like building a new playground, putting in a community garden, or 
creating a wheelchair fund that could be used to help purchase wheelchairs, walkers, or 
assisted living devices to help persons achieve greater mobility and freedom in their 
living environments. Companies can also use the savings to offer scholarships to students 
pursuing courses and majoring in PV. 
A Review of the Professional and Academic Literature 
The purpose of this qualitative single case study was to explore the strategies that 
PV systems managers in the pharmaceutical industry use to implement innovative 
technology solutions to automate AE case processing. As observed by Saunders et al. 
(2015), critical analysis and synthesis of the literature provided the context and 
theoretical framework for my research relating to application of innovative technology 
like AI or robotics-based solutions for PV. My goal was to identify knowledge gaps, 
provide a foundation to legitimize the research question, and justify the current study and 
research objectives (Azungah, 2018; Saunders et al., 2016). This section includes the 
findings of an integrative review that I conducted to understand the function of PV and its 
challenges, perspectives of technology on PV and AE reporting, and the conceptual 
framework based on technology adoption models and theories. 
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The literature review consisted of journal articles and book chapters (as shown in 
Table 1) relating to the PV function focusing on technology and the pharmaceutical 
industry, and the theoretical background of the technology adoption models specifically, 
TTF and technology acceptance model (TAM), and chaos theory (Faggini & Parziale, 
2016; Lorenz, 1963). The literature review included an integrative review of articles from 
Walden University library, Google Scholar, PubMed, and ProQuest databases. Key 
search terms for conducting research for the literature review included: technology 
adoption, innovative technology, pharmacovigilance, drug safety, adverse reaction 
reporting, adverse drug event reaction in combination with strategy, conceptual 
framework, technology acceptance, TAM, TTF, chaos theory, and qualitative research or 
a combination of keywords. Throughout the study, the terms AEs, adverse reactions, and 
case reports are used interchangeably. The terms drug product, medicines, drug, and 
product are used interchangeably. The study included 176 references out of which 141 
(80%) were published in or after 2016. 
Table 1 
 
Source of Data for Literature Review 
 Total Total Published in 
or After 2016 
% Published in or 
After 2016 
Peer-reviewed journals 88 80 91% 
Books 2 2 100% 
Non-peer-reviewed journals 15 14 93% 
Total 105 96 91% 
 
This academic literature review section is split into two subsections and is 
structured as follows: (a) technology adoption models: TTF model, including TAM as the 
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supporting model and chaos theory as the contrasting theory and (b) an introduction to 
PV including health information technology: the importance of the PV function and AE 
reporting for the health authorities, the pharmaceutical industry, automation, and 
innovative technology implementation, including the challenges and risks. I present the 
informatics and technology perspective including the challenges and opportunities. 
Technology Adoption Models and Theories 
Researchers have used the technology adoption models and diffusion theories to 
build a foundation for studies to understand innovation adoption and diffusion (Jha & 
Bose, 2016). In their study to understand the developments in the field of innovation 
research in information systems, Jha and Bose (2016) analyzed articles published in the 
past 15 years to conclude that technology acceptance models and diffusion theory are the 
most popular. During the exploration for a conceptual framework for my study, I 
analyzed technology acceptance models and decided on the task technology fit or the 
TTF model. Diffusion theory is a change model for adoption of technological innovations 
and helps in identifying the perception factors of innovation that influence adoption of 
innovative technology (Emani et al., 2018). Because I focused on implementation of 
innovative automation technology and not particularly perception of innovation and 
adoption, I believed the TTF model constructs provided better guidance to achieve the 
objective of this study. I have described The TTF model, and the applicability of the TTF 
model constructs to this study in this section. Overreliance on a theory can lead to 
confirmation bias with researchers looking for evidence to match the existing conceptions 
(Collins & Stockton, 2018). Therefore, as guided by Collins and Stockton (2018), I used 
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the constructs of the TTF model as a tentative theory or a map to understand the 
phenomenon.  
TTF model. Goodhue (1995) proposed the TTF model to evaluate and measure 
success of information systems and posited that a high task-technology fit would 
positively impact the performance. Goodhue and Thompson (1995) proposed the TTF 
model by empirically testing the link between IT and individual performance to assert the 
utilization of technology and that the technology must be a good fit for the tasks it 
supports. TTF links the task requirements, individual abilities, and the functionality of 
technology (Goodhue & Thompson, 1995), as shown in Figure 1. Goodhue and 
Thompson (1995) concluded their research based on data collected from questionnaire 
responses from 600 individuals from two companies. Lai (2017) summarized the TTF 





Figure 1. Task-technology fit model constructs. Adapted from “Task-technology fit and 
individual performance,” by D. L. Goodhue and R. L. Thompson, 1995. MIS Quarterly, 
19(2), p. 213. 
TTF is a simple model that matches the tasks with the ability of a technology to 
address the events as they occur. TTF theory focuses on the application and the general 
reliance on technologies and does not recommend any task or technology pairings that 
could produce a strong effect (Howard & Rose, 2019). Common constructs are associated 
with the outcome of the task and technology fit, like performance, user reactions, utility, 
perceived utility, and utilization, and not the TTF model itself. Howard and Rose (2019) 
believed that the narrow scope of TTF theory may be the reason for alterations and 
inappropriate inferences, which may be rectified by extending TTF theory to better fit a 
wide range of settings. 
Taherdoost (2018) performed a literature review of technology adoption models 
and noted that most information system researchers did not separate the affective 
emotional component of attitudes of like/dislike and the cognitive component of 
information a person holds about an object, issue, or person. Both cognitive processes 
and emotional and affective elements influence behaviors (Taherdoost, 2018). Therefore, 
integration of different models would help achieve the greater comprehensive view of the 
objectives of the research (Sombat et al., 2018; Dishaw & Strong, 1999). 
Researchers have improvised the TTF model by incorporating other theories such 
as the technology-based models like TAM and the appropriation theories. TAM and TTF 
are two foremost models of information technology utilization and adoption (Dishaw & 
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Strong, 1999; Lai, 2017). The integrated TAM/TTF model combines an 
attribute/behavior model (TAM) with models of the task and technology fit with a 
conclusion that TTF constructs directly affect technology utilization and indirectly affect 
the technology utilization using TAM’s variables alone (Dishaw & Strong, 1999). 
Dennis, Wixom, and Vandenberg (2001) introduced the fit-appropriation model by 
integrating TTF with the appropriation support the group receives in the form of training, 
facilitation, and software restrictiveness. Park (2019) proposed content characteristics 
such as knowledge, information, and data as a new determinant of fit to improve the 
explanatory power of TTF. 
TAM. TAM was introduced by Fred Davis in 1989 (Davis, 1989) and is one of the 
most widely used models for technology acceptance (Lai, 2017; Taherdoost, 2018). TAM 
as a supportive model explains the causal relationship between a user’s acceptance of 
technology and actual usage (Sombat, Chaiyasoonthorn, & Chaveesuk, 2018). TAM 
identifies ease of use and perceived usefulness to determine the user’s attitude toward 
technology, intention to use, and actual use (Dishaw & Strong, 1999). Researchers can 
use TAM to explain the causal relationship between user’s acceptance of technology and 
actual usage (Sombat, Chaiyasoonthorn, & Chaveesuk, 2018). TAM identifies ease of use 
and perceived usefulness to determine the user’s attitude toward technology, intention to 
use, and actual use (Dishaw & Strong, 1999). 
Integrated TAM/TTF model. To understand the how customers use the software 
and how the software functionality fits the perceived needs of the user, Dishaw and 
Strong (1999) provided an integrated TAM/TTF model. Integration of TAM and TTF 
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offers a stronger model because the variable constructs overlap in a certain way (Sombat 
et al., 2018). Dishaw and Strong (1999) devised the integrated model based on study data 
from questionnaire responses from three established firms from financial services, 
aerospace manufacturing, and insurance industries. The questionnaire contained items for 
each TAM variable: intention to use, attitude toward use, perceived ease of use, and 
perceived usefulness (Dishaw & Strong, 1999). The integrated TAM/TTF model 
combines an attribute/behavior model (TAM) with models of task-technology fit with a 
conclusion that TTF constructs directly affect technology utilization and indirectly affect 
the technology utilization using TAM’s variables alone (Dishaw & Strong, 1999). Since I 
focused on selection and implementation of innovative technology in this study, the 
constructs of the TTF framework was deemed to be a better match in achieving the 
objectives of my study. 
Chaos theory. Henri Poincare introduced the chaos theory with a principle that 
systems tend to self-organize to adapt to continuing challenges to overcome chaos 
(Faggini & Parziale, 2016). As a contrasting theory for this study, chaos theory can assist 
in understanding of the unpredictability of a system’s behavior. To demonstrate the chaos 
theory, Lorenz (1963) used the butterfly effect, which is a phenomenon that generates 
small changes in the input but distributes dramatic consequences in the output. The chaos 
theory helps researchers understand how complex systems work and what causes 
ambiguity regarding the behavior of the dynamic systems. 
In the perspective of technological innovation, Li and Wang (2019) found that 
chaos of the system is visible when the technological content is larger. Therefore, Li and 
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Wang (2019) summarized that companies use optimal technological contents to obtain 
maximum profits. Since the innovative technology solutions are a recent development for 
PV, the pharmaceutical companies implement and operate with optimal solutions to 
balance the profit margins with the stability of the market (Li & Wang, 2019) despite the 
need of using technological innovation to create competitive advantage. 
Based on the literature review of original models and integrated models for 
technology implementation, as described in this paper, I chose the TTF model for my 
research study. Because a qualitative study is inductively grounded and based on 
philosophical and ethical grounds, my research could have followed a structured or 
unstructured approach, as guided by Cypress (2018). An inductive approach is used to 
explore a phenomenon and identify themes to create a conceptual framework (Saunders, 
Lewis, & Thornhill, 2015).  
Researchers have applied the TTF model in a healthcare setting where business 
needs technology solutions. Ali, Romero, Morrison, Hafeez, and Ancker (2018) applied 
the TTF framework to evaluate how a patient portal helped improve the portal's fit to 
patient needs. The study concluded that patients lack a clear understanding of tasks that 
would help them accomplish personal health information management (Ali et al., 2018). 
Because my research topic included new strategies PV systems managers use to 
implement innovative technology, an unstructured inductive qualitative study based on 
the constructs of the TTF model assisted in achieving my study objectives. 
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PV and Healthcare Information Technology 
In this section, I will describe the findings of the integrative review to understand 
the business of PV and IT in the pharmaceutical industry. This section includes PV-
related topics such as the function of PV, mandated AE reporting, and related challenges 
like product recalls and AE detection and reporting. This section of the literature review 
also includes the perspectives of technology on PV and AE reporting, digital PV, 
automation, innovative technology implementation trends and risks, and implementing 
innovative technology for PV business processes.  
PV. A search for approaches for pharmacovigilance or drug safety revealed a 
variety of research studies. PV is studying the safety and effectiveness of drugs including 
the activities relating to detection, assessment, understanding, and prevention of the AE 
associated with the use of drugs (Beninger & Ibara, 2016; Lu, 2009; World Health 
Organization, 2019b). A marketing authorization (MA) holder must prove a drug 
product’s safety, efficacy, and quality to obtain a product license to market it (Lewis & 
McCallum, 2019). A drug product or medicine will gain a marketing authorization after a 
regulatory agency conducts comprehensive reviews of the drug product to evaluate the 
benefits and risks (Schurer, Bam, & de Kock, 2017), finds a favorable benefit-risk 
balance, and approves the drug product to be marketed within jurisdiction of the relevant 
agency. 
When a drug product is marketed, and the drugs are used by large populations, 
unexpected adverse reactions or AEs may occur, which changes the risk-benefit ratio of 
the drugs, requiring a regulatory action in post marketing surveillance (Pitts et al., 2016). 
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AE is unexpected harm caused by the normal use of medication at the normal dosage 
(Karimi et al., 2015). No medicine is safe at the time of approval for sale or marketing 
authorization (Pitts et al., 2016). Only when the benefit of taking the drug outweighs the 
risks, consuming a drug can be justified (Kothari et al., 2018). Since clinical trials are 
conducted in a controlled environment with a small set of human patients, the adverse 
reactions and AEs collected are not representative of the large population that will 
consume the drug. AE from consuming drugs could remain undetected, exposing 
consumers to the unexpected risks and harm in the absence of a robust AE reporting 
system (Bailey et al., 2016). Therefore, the early detection, observation, and analysis of 
AE in the post-marketing period to identify the risks associated with the consumption of 
drugs (Munoz et al., 2020; Tan et al., 2016) and protect patients from unnecessary harm 
is a key goal of a PV system. 
Drug safety is a priority for both the health agencies worldwide and the 
pharmaceutical industry. In the European Union, about 197,000 deaths are caused by AEs 
per year and the total cost to society of AEs is €79 billion (Mohiuddin, 2018). AEs are 
unexpected effects occurring from normal use of drugs taken in normal dosage (Basile et 
al., 2019). In 2013, medical errors including AEs were identified as the third leading 
cause of death in the United States (Makary & Daniel, 2016). Health authorities and 
agencies have implemented multiple mechanisms to monitor the safety of the drug 
products across the discovery, development, and marketed phases like the Center for 
Drug Evaluation and Research (CDER), the New Drug Application (NDA), and Post-
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marketing Surveillance (PMS) program to assess and monitor drug safety risks by the 
U.S. FDA (Tan et al., 2016). 
Unsafe healthcare causes harm and leads to other forms of collateral damage such 
as loss of trust in the system and loss of reputation and credibility in health services 
(World Health Organization, 2017). The occurrence of AE is one of the top 10 causes of 
death and disability across the world (World Health Organization, 2019a). Officials of the 
World Health Organization reported that 134 million adverse events occur each year in 
hospitals, contributing to 2.6 million deaths annually due to unsafe care (World Health 
Organization, 2019c). 
Drug product recalls. Delayed detection of AEs can lead to legal risks and huge 
expense for a pharmaceutical company. Serious AEs can lead to drug recalls, market 
withdrawals, and safety alerts and can cost the company financially and loss of consumer 
trust and are an important safety issue for patients and healthcare providers (Hall et al., 
2016; Liu, Zhao, & Zhang, 2016). A review of U.S. FDA recalls showed that AE was one 
of the top three reasons for drug recalls, which could cost a large pharmaceutical 
company $900 million (Hall et al., 2016). 644 products were withdrawn from the market 
because of AEs between 1953 and 2013 (Onakpoya, Henegan, & Aronson, 2016). The 
withdrawal of anti-inflammatory rofecoxib (Vioxx™) occurred only after millions of 
patients had been exposed, highlighting the need for earlier, more comprehensive data 
reporting (Bailey et al., 2016). Evidence from spontaneous reporting of AE and clinical 
research studies are used to support the decisions for revoking marketing authorization 
and withdrawal of products (McNaughton et al., 2014). Therefore, pharmaceutical 
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companies and MA holders must identify AEs at the earliest to avoid the expenses from 
recalls due to AEs and assist with patient safety. 
Sources of AE. MA holders are required to collect, and report AE cases reported 
by patients by 2012 PV legislation (Kothari et al., 2018). Each national drug agency 
collects its own AEs in a database, so do the MA holders. Companies use relational 
databases to collect, store, and process AEs, which are linked to data warehouses that are 
used for reporting AEs to the health authorities (Lewis & McCullum, 2019). Sources of 
AE data include literature including mass media, clinical trials, observational studies, 
spontaneous reporting data analysis, case reports, clinical, non-clinical, and preclinical 
data (Onakpoya et al., 2016; Rasch et al., 2019; Schurer et al., 2017). Spontaneous 
reporting systems contain high quality data and have been the primary source of AEs 
traditionally (Kothari et al., 2018; Raschi et al., 2019). Recently due to increased 
awareness, multiple countries allow patients to directly report AEs. Patient reporting is an 
important source for AEs, which has increased recently despite challenges with reporting 
systems and confusions with reporting (Inacio, Gomes, Airaksinen, & Cavaco, 2018; 
Mohiuddin, 2018). Patients, manufacturers, and healthcare professionals report AEs 
(Schurer et al, 2017) in variety of ways by phone calls, e-mails, and report directly to the 
manufacturers and the health authorities or discuss on social media such as blogs and 
social networking sites. Typical process of collecting, processing, and reporting AEs 






Figure 2. Typical process for AEs case processing and reporting within a marketing 
authorization holder. Adapted from “Utilizing advanced technologies to augment 
pharmacovigilance systems: Challenges and opportunities,” by D. J. Lewis and J. F. 
McCallum, 2019. Therapeutic Innovation & Regulatory Science, p. 2. 
High volume of cases reported creates a challenge for governance to perform PV 
(Mitchell, Schuster, Smith, Pronovost, & Wu, 2016). Though there is an exponential 
increase in the number of AEs reported, under-reported, inaccurate, and delayed post 
marketing spontaneous cases is a challenge for PV (Elkin, Johnson, Callahan, & Classen, 
2016; Pitts et al., 2016; Schurer et al., 2017). Traditional AE data sources such as 
spontaneous reporting data, electronic health records, pharmaceutical databases, and 
biomedical literature are limited by under-reporting ratio, privacy issues, high cost, or 
long publication cycle (Yang & Yang, 2018). Despite being obligated to participate in the 
PV process and spontaneous AEs reporting, pharmacists do not fully comply (Kopciuch 
et al., 2019). Only 16% of pharmacists were found to be trained in PV in Poland 
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(Kopciuch et al., 2019). Nurses generally report AEs since doctors are not engaged and 
do not report AEs, which causes bias and missed critical diagnosis (Mitchell et al., 2016). 
Under-reporting is a result of non-standard reporting process, inadequate knowledge of 
reporting, negligence, time constraints, and gaps in safety information systems 
(Mohiuddin, 2018). The median under-reporting rate was 94% (Lexchin, 2015). Only 5-
10% of AEs are reported and about 95% of health care professionals do not report AEs 
(Mohiuddin, 2018). Under-reporting of AEs could cause delays in making decisions 
regarding withdrawing the drugs from the markets (Onakpoya et al., 2016). Standardizing 
reporting and encouraging patient reporting by creating a safe and secure environment 
can improve voluntary spontaneous reporting and reduce incomplete and insufficient data 
(Schurer et al., 2017). Padgett, Gossett, Mayer, Chien, and Turner (2017) recommended 
organizations transition into high-reliability organizations in order to increase AE 
reporting, which could contribute to industry-wide improvement in patient safety and 
reduce operational costs. 
The information about the type and variety of AE data elements collected within 
AE reporting systems varies internationally. Timely communication of AEs is a challenge 
though the AEs are recognized sooner (Lexchin, 2015). Bailey et al. (2016) identified 108 
reporting systems, containing 1,782 unique data fields mapped to 33 reporting concepts. 
A minimum required dataset for a valid AE case report included an identifiable patient, 
an AE, a suspect medicinal product, and an identifiable reporter. However, the absence of 
standardized AE data collection and reporting data elements and variations across 
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systems rendered aggregate reporting a challenge, which directly affected safety 
surveillance (Bailey et al., 2016; Schurer et al., 2017).  
With the increase in awareness about AE reporting, regulatory agencies have 
improved their safety surveillance guidance for the MA holders (Stergiopoulos, Fehrle, 
Caubel, Tan, & Jebson, 2019). Since the spontaneous reporting of AEs is biased with 
challenges, PV function leaders from the industry and the regulatory agencies are 
exploring other sources and advanced computational methods to supplement existing 
methods (Basile et al., 2019; Toki & Ono, 2018). Many researchers have concluded that 
social media is a good source of AE information and that technology can be used in 
social media mining to find cases (Pitts et al., 2016). However, based on a systematic 
review, Convertino, Ferraro, Blandizzi, and Tuccori (2018) concluded that despite the 
possibility of mining AE data quicker from social media than traditional spontaneous 
reporting, the poor quality of information makes it a challenge for social media to be 
considered a viable source of AE for PV. The user posts on social media contain 
colloquial language and misspellings, which disrupts the balance between sensitivity and 
specificity in identifying AEs (Raschi et al., 2019). 
The current process of collecting and processing AE in the pharmaceutical 
industry is manual, complex, and poses high risk of errors. The challenges on the 
pharmaceutical industry’s perspective include the management of the high volume of 
AEs, globally diverse and changing regulations, complex and evolving systems, and 
sparse PV expertise and talent (Price, 2018). In 2019, the U.S. Food & Drug 
Administration received 2.2 million AEs (“FDA adverse event”, 2019), which is a 450% 
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increase since 2009 and increased AE-related operational costs for pharmaceutical 
companies. Pharmaceutical companies must invest in PV to avoid risks and frequently 
manage PV as a cost-center. Processing of an AE is an expensive resource-intensive 
process, which includes high risk of errors and operational inefficiencies (Ghosh et al., 
2020). The increasing costs of PV have led to outsourcing of PV activities to service 
providers operating in low-cost locations (Price, 2018). A continuous, digitized, 
automated data management within a computerized system that leverages AI, machine 
learning, and blockchain can address the talent shortfall (Price, 2018) and refocus the PV 
effort from data management toward ensuring effective use medicines. 
Healthcare information technology. Healthcare information technology is the 
application of computers for the storage, retrieval, sharing, and use of health care 
information, data, and knowledge for communication and decision making (Alotaibi & 
Federico, 2017). Marante (2018) posited that clinical experience could not be 
contemplated in the algorithms, and that contributes enormously to the establishment of 
the causal relationship between a product and AE. However, Marante (2018) concluded 
that the clinical judgment method poses difficulties in standardization of evaluation; and 
therefore, a need for a universally accepted high-quality assessment tool.  
Recently, innovative technologies are impacting the way companies process and 
evaluate AEs. Beninger and Ibara (2016) and Donzanti (2018) summarized that the 
rapidly developing innovations in informatics pose challenges for PV, however, offer 
opportunities for close collaboration. Innovative technologies like robotics and AI have 
permeated the pharmaceutical industry and assist in enhancing the drug discovery process 
26 
 
and reducing the research and development effort (Agrawal, 2018; Donzanti, 2018). 
Implementing AI technologies can be a breakthrough for the future market sustainability 
of biopharmaceutical organizations (Agrawal, 2018). 
Automation. The pharmaceutical industry is actively engaged in an automation 
race. Automation is an intelligent organizational process that delivers responsiveness and 
agility, which is created as an outcome of effective usage of technology like robotics 
(Buyukozkan & Gocer, 2018). Automation accelerates innovation by increasing 
productivity and relieving human resources, which can lead firms to gain significant cost 
and competitive advantages (Bal & Erkan, 2019; Nylund, Ferras-Hernandez, & Brem, 
2018). Technology and innovation are two of the five top factors leading to economic 
success (Bal & Erkan, 2019). Expert systems use an inference or cognitive engine, which 
provide information by replicating the decision-making processes performed by a human 
expert (Tomita, 2019). Investing in and implementing emerging technologies will create 
a sustained competitive advantage for companies through enhancing access to 
information, reducing costs, improving products quality, as well as responsiveness, and 
collaboration abilities (Agrawal & Narain, 2018). By investing in automation, companies 
generate value by lowering expenses on human resource and increasing revenue and 
productivity though process innovation (Nylund et al., 2018). Companies who have 
embraced digital strategies are seeing real value, boosting revenue more than 9%, market 
valuation more than 12%, and profitability by over 26% (Rakowski, 2015). 
Pharmaceutical industry as a business sector is a slow adopter of new and 
emerging technology for automation like artificial intelligence (Lewis & McCallum, 
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2019; Streefland, 2018). Most healthcare organizations face challenges to innovate in 
terms of management, systems, and culture, despite recent innovation practices like open 
innovation and innovative management practices (Kim, Gaukler, & Lee, 2016). 
Companies attempt to incorporate automation into all functions, including research and 
development (R&D) and PV. For example, cognitive technology-based systems like IBM 
Watson can leverage Big Data to improve insight and accelerate life sciences discoveries 
(Chen, Elenee Argentinis, & Weber, 2016). Investing in automation in PV can provide 
better quality of safety data quickly with lesser manual effort (Lewis & McCallum, 
2019). PV systems managers focus on the development, acquisition, and incorporation of 
related technologies to profit from automation. Most companies partner with suppliers 
who possess the expertise with automation technologies and invest in co-innovation 
based on a knowledge sharing and open innovation strategy (Nylund et al., 2018; 
Trantopoulos, von Krogh, Wallin, & Woerter, 2017). Another critical aspect is 
organization culture.   
An organization must have a common culture that is aligned with the 
organizational goals. Organizations are exposed to technology, globalization, and cutting-
edge production, which result in creation of new organization structures, business 
processes, and ways of working (Fusch, Fusch, Booker, & Fusch, 2016). Leaders must 
invest in building a resilient organization with an innovative culture that can withstand 
the exposure and maintain their competitive edge. 
While planning for a digital future, company managers must critically evaluate 
the technologies and business models they can adopt to reach their objectives. Selecting 
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the most suitable technological solutions and reaping the maximum benefits of the digital 
means requires companies to internalize digitalization as an integral part of their overall 
operations methodology and their organizational structure (Buyukozkan & Gocer, 2018). 
Dalenogare, Benitez, Ayala, and Frank (2018) recommended companies targeting 
differentiation focus on product development technologies and those targeting low cost, 
productivity or operational flexibility can prioritize manufacturing technologies. 
Innovative technology implementation trends. Organizations can incorporate 
innovation externally from a supplier or partner by joint development, which is more 
suitable for customer-supplier collaborations. With an emphasis on external collaboration 
to encourage and implement open innovation, Rodriguez-Ferradas and Alfaro-Tanco 
(2016) presented strategies for small and medium enterprises to collaborate with different 
kind of partners. For example, innovation contests can be used for company-university 
collaborations.  
Organization leaders have realized that proactive external collaboration is 
beneficial for creation of new products and solutions (Di Fiore, Vetter, & Capur, 2017). 
Di Fiore et al. (2017) identified four specific areas of benefits:  
• deeper knowledge: collaboration between experts and end users offers in-
depth knowledge of the business context of use. 
• lower marketing costs: collaboration based on joint development and 
testing partnership can lower marketing costs. 
• decreased risks: innovation driven by direct collaboration with the end 
users produce solutions with lower risk and fit the business purpose better. 
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• increased trust: close collaboration improves relationship and increase 
trust between the partners. 
Different open innovation practices can be utilized for new product development 
in companies collaborating with different kinds of partners (Rodriguez-Ferradas & 
Alfaro-Tanco, 2016). Organizations must internalize digitalization and incorporate in the 
operations methodology and structure in order to select the most suitable technological 
solutions and reap the maximum benefits (Buyukozkan & Gocer, 2018). Rose, Jones, and 
Furneaux (2016) and Trantopoulos et al. (2017) identified knowledge, innovation 
management, and the team process as the significant innovation drivers in small and 
medium sized enterprises.  
Organizations engage in outsourcing of transactional systems to enable service 
innovations or new product development in the form of contract agreements (Susarla & 
Mukhopadhyay, 2019). Automation and cognitive systems have permeated service 
management to a next generation of integrated network, systems, and service 
management (Keller, 2017). Service management is built based on service level 
agreements with the outsourcing partner, which can be hosted on cloud or traditional or 
hybrid setups blending cloud with traditional or virtualized on-premise infrastructure 
(Keller, 2017). 
To enable business model innovation, organizations with inhouse digitization and 
IT development capabilities can adopt agile development methodology. Agile 
development refers to practices for software development based on iterative and 
incremental delivery of working software, collaboration with customers and response to 
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change (Ghezzi & Cavallo, 2018). Managers have multiple options to implement 
technologies and value propositions and adopt a leader or follower strategy in the 
digitization arena (Ritter & Pedersen, 2019). Since innovative technology does not 
provide any guarantees, companies leverage iterative ideation and experimentation. 
Innovative technology risks. There are multiple risks associated with using 
technology for competitive advantage. Thorough analysis of all innovation stages is 
required when innovation is considered, owing to the complex multistage nature of the 
innovation process and lifecycle (Jha & Bose, 2016). Carr (2003) called IT a commodity 
and strongly recommended focusing on the risks rather than the strategic advantages it 
provides. A disruption to IT supply can paralyze a company. Overspending on IT can 
place a company at a cost disadvantage. Sourcing of technology development, support, 
and management of IT functions from vendors introduces risks. Companies must 
carefully invest in technology and IT solutions because great spending on IT does not 
equate to superior financial results (Carr, 2003).  
Managers might not understand the implications of disruptive technologies 
because their views of the world are shaped by their prior experiences of technologies 
and markets (Vecchiato, 2017). Innovative technology can lead to cultural changes in the 
organizations progressing toward building a smart, creative and dynamic innovation 
culture (Keles, & Battal, 2017). Change is difficult, the managers must use the right 
strategies to communicate and motivate the team members to build an innovative culture 
(Eggers & Kaul, 2016). 
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Despite the various advantages and benefits of external collaboration for 
innovation initiatives, many innovations fail to deliver the expected successful outcomes 
and lead to significant value creation (Di Fiore et al., 2017). Di Fiore et al. (2017) 
identified the following four traps that collaboration can lead to and potential solutions to 
avoid them: 
• treating collaboration as an event. Instead, manage collaboration like a 
seamless process. Innovation requires careful planning, agreeing on ways-
of-working, intellectual property management, resource management, and 
defined oversight and governance.  
• defining the problem statement alone. Instead, co-design the problem 
statement. All the parties and stakeholders involved must be in complete 
agreement on the problem that is being solved to ensure the solution 
matched the business need and problem. 
• diverging time horizons. Instead, generate value across multiple time 
horizons. Shared understanding of the timeline expectations will drive the 
resource allocation and management, which will directly impact the 
financials. Time span and financial goals must be defined upfront with 
transparency. 
• failure to generate empathy. Instead, empathize throughout the process. 
During the collaborative innovation process, the stakeholders must include 
the human or end-user perspective in the ideation stage of the process. 
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Digital PV. Digitalization involves using digitized data to make decisions and 
generate change (Gobble, 2018). Gobble (2018) further explained that the digitalization 
process leads to digital transformation, which is the re-structuring and re-defining of the 
business organizations considering opportunities from emerging technology. Digitization 
and innovations like Big Data and analytics have led to new operating models in multiple 
functions within healthcare industry, but, not PV (Beninger & Ibara, 2016). Karimi et al. 
(2015) summarized that drug safety had not been comprehensively surveyed from the 
viewpoint of computer science to understand the influence of technology on drug safety 
detection. 
Schmider et al. (2018) summarized that despite the significant opportunity 
provided by PV, there are no comprehensive technology solutions for expensive process-
AE processing and reporting. Beninger and Ibara (2016) concluded that both the fields 
PV and informatics have separately grown exponentially, with a substantially low rate of 
overlap between the two despite the increase in awareness of innovative technology in 
PV. Beninger and Ibara (2016) presented a detailed analysis of the PV adverse event case 
processing process and the corresponding technology used starting from relational 
databases and faxes to the recent technology like Blockchain and artificial neural 
networks. Beninger and Ibara (2016) identified advanced technology like AI for PV is 
emerging and growing and concluded with an emphasis for implementing informatics 
and developing structures to facilitate an approach to adopt informatics. Prior to 
deploying automation, organizations must embark on a business process re-engineering 
journey (Mishra, Devi, & Narayanan, 2019). 
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In 2014, the FDA received 528,192 new AE reports indicating a serious or fatal 
outcome, 4.7% directly from health professionals and consumers, and 95.3% from drug 
manufacturers (Moore, Furberg, Mattison, & Cohen, 2016). Majority of the AEs received 
by the FDA are from the manufacturers and MA holders since most AEs are reported 
directly to the manufacturers (Stergiopoulos, Brown, Felix, Grampp, & Getz, 2016). A 
study on AE quality and completeness by Moore et al. (2016) concluded that the report 
completeness from drug manufacturers was poor compared with direct submissions. 
More than one third of the AEs submitted by the manufacturers did not include basic 
information to establish a causal relationship between an AE and a drug product, which 
can be an issue for the detection of safety signals (Plessis, Gomez, García, Cereza, & 
Figueras, 2017). Innovative technology including new algorithms and data mining tools 
can assist in improving the quality and timely extraction and reporting of AEs (Lewis & 
McCallum, 2019; Plessis et al., 2017). The future of adverse event reporting had to take 
full advantage of the rapidly developing electronic health records and technologies to 
automate voluntary reporting of incidents (Mitchell et al., 2016).  
A study by Ribeiro, Motta, Marcondes-Fonseca, Kalil-Filho, and Giavina-Bianchi 
(2018) revealed that in a hospital setting, there were a total of 94 adverse drug reactions 
in 75 patients and most reactions were predictable and of moderate severity. For each 
medication introduced during hospitalization, there was a 10% increase in the rate of AEs 
with the probability of observing an AE was 1 in 104 patients per day. 134 million AEs 
occur each year in hospitals, contributing to 2.6 million deaths annually due to unsafe 
care (World Health Organization, 2019c).  
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Proactive prevention of risks can be achieved using AI for analysis of data from 
post marketing studies, electronic medical records, and the Internet among other trends 
(Fermont, 2019). Organizations must understand and identify the opportunities and 
implications of implementing innovative technology to add value at a conceptual level 
(Lewis & McCallum, 2019) as shown in Figure 3. Despite multiple successful 
experiments with using innovative technologies to improve performance and efficiency, 
the primary challenges are transparency and traceability (Spasic, Uzuner, & Zhou, 2020). 
 
 
Figure 3. PV systems automation: Conceptual diagram showing the different entities 
relating to PV systems automation. Adapted from “Utilizing advanced technologies to 
augment pharmacovigilance systems: Challenges and opportunities,” by D. J. Lewis and 
J. F. McCallum, 2019. Therapeutic Innovation & Regulatory Science, p. 2. 
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Leaders must adopt a systems thinking approach and focus on systems, processes, 
and measures to build a learning organization which is both reliable and resilient 
(Gossett, Padgett, Pierce, & Scott, 2019). Emerging technology and intelligent 
automation in the PV business systems function is complex, and are not readily 
understandable by the PV business professionals who are trying to implement them 
(Lewis & McCallum, 2019). Eseryel (2019) summarized three strategies for non-IT 
managers to achieve digital business transformation: create and procure endorsement for 
an IT-enabled business transformation vision, develop a change management function for 
the transformation, and build a strong non-IT business leadership team. 
Lewis and McCallum (2019) envisioned all stakeholders within the PV industry 
working on a single database that is based on blockchain technology. Arlett, Straus, and 
Rasi (2019) made three predictions for PV, by 2030 PV function will be smarter in 
collecting and reporting of AE, measurement of on‐market performance of medicines, 
and improved engagement of patients and healthcare professionals. Streefland (2018) 
highly recommended the PV system to focus on the patient rather than on regulations and 
recognized a need to work toward optimal analysis of real-time medicine use insights, 
instead of AE creation, reporting, and adherence to procedures. 
Innovative technology trends in PV. Mesko (2017) recognized that medicine 
requires a variety of disruptive technologies to be implemented into developing 
treatments, practicing medicine, and delivering care. Recent developments in the 
innovative technologies include text analytics, robotic process automations, cognitive 
technologies including machine learning and deep learning. Since rule-based 
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technologies are traceable, the applications are abundant. Despite multiple successful 
experiments with using these innovative technologies to improve performance and 
efficiency, the primary challenges are transparency and traceability (Spasic et al., 2020).  
Ghosh et al (2020) considered the innovative automation technologies like natural 
language processing (NLP), AI, machine learning, optical character recognition, and 
robotic process automation (RPA) as “intelligent” since they are more advanced. Ghosh 
et al. (2020) also predicted that the risk of failure or malfunction of these technologies 
will reduce over time as the technologies evolve. The automation requirements for small 
and mid-size companies might be different from large companies since they may have 
specific process approaches that may not be conducive for automation (Ghosh et al., 
2020). 
RPA is an automation technology that can be used enterprise-wide to automate 
repetitive manual processes which are rule-based, thereby enabling manual resource cost 
savings, reducing errors, and improving efficiency (Dey & Das, 2019). Carden, 
Maldonado, Brace, and Myers (2019) listed accuracy, audit trail, consistency, flexibility, 
location agnostic, low-risk and non-invasive technology, productivity, reliability, 
availability, and productivity as the value proposition for RPA. RPA software robots 
(bots) only work on the user interface, which are simple to develop and do not require 
complex programming (Phillips & Collins, 2019). Phillips and Collins (2019) compared 
bots, which follow a set of rules with AI-based solutions, which are neural networks 
designed to replicate human brain process. Since bots are straight forward and rule-based, 
they can be built to replace any repetitive and mundane tasks and applied in any industry. 
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RPA can be applied successfully for PV; however, the PV systems managers and the 
business users must work closely to identify highest potential processes and identify the 
most beneficial automation approach (Carden et al., 2019; Phillips & Collins, 2019). 
Innovative technology must be used intelligently. For example, processes that involve 
decision making, the RPA solutions must be blended with AI-based cognitive solutions 
(Mishra et al., 2019) 
Multiple researchers have identified a variety of applications for text analytics in 
the healthcare and pharmaceutical clinical functions such as triaging patients, decision 
support, clinical research, and PV (Spasic et al., 2020). In the recent years, clinical NLP 
systems have matured to accurately extract medical information buried in texts that 
contribute to PV (Tan et al., 2016). Schmider et al. (2018) conducted a pilot test to verify 
the feasibility of using AI and robotics to automate the processing of AE reports. The 
results confirmed the viable use of AI-based solutions for AE case processing regarding 
extraction of case information by training the machine learning algorithms (Schmider et 
al., 2018). NLP can structure and customize automatically extracted AE information and 
store in a way that healthcare professionals can specifically share AEs that are of the 
individual patients’ interest (Kusch, Zien, Hachenberg, Haefeli, & Seidling, 2020). NLP 
can be used to detect healthcare associated infections in hospital facilities and NLP chain 
processing can facilitate a standardized AE detection process across multiple hospitals 
(Tvardik et al., 2018). 
Social media is a potential rich source of AEs. Considering the median under-
reporting rate of AE to be 94% in spontaneous reporting systems, social media and 
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crowd-sourced data can be potential sources to detect AE related to health products 
including pharmaceuticals, medical devices, biologics and natural health products 
(Tricco, Zarin, Lillie, Pham, & Straus, 2017). Despite the possibility of mining AE data 
quicker from social media, poor quality of information makes it a challenge for social 
media to be considered a viable source of AE (Convertino et al., 2018). Data from social 
media is not rich because of the use of slangs and colloquial posts, which cause a 
negative impact on the AE extraction program (Arnoux-Guenegou et al., 2019). In their 
study, Gattepaille, Hedfors Vidlin, Bergvall, Pierce, and Ellenius (2020) concluded that 
there was a large discrepancy between the expected and actual results of automatically 
identifying AEs from Twitter. The authors justified the lack of an all-purpose automated 
social media AE extraction solution in the industry was potentially due to the challenges 
with practical AE detection from independent data. 
Complex medical concepts can be extracted from informal, user generated 
content. Nikfarjam, Sarker, O’Connor, Ginn, and Gonzalez (2015) devised a machine 
learning-based approach that was scalable and suitable for social media mining, as it 
relied on large volumes of unlabeled data, which removed the need for large, annotated 
training data sets. Yang and Yang (2018) developed a framework to facilitate drug safety 
signal detection by harnessing online health community data, a timely, informative, and 
publicly available data source like MedHelp, which collected patient-contributed content. 
Advanced NLP techniques like feature-based and kernel-based methods that can 
effectively identify and separate AEs and non-AEs from the informal text in the social 
media (Liu et al., 2016).  
39 
 
Cognitive technologies have proven to successfully detect AEs in experimental 
setting. Based on multiple pilot projects, Chen et al. (2016) summarized that IBM Watson 
can assist the drug safety process through faster recognition and coding of AE from text. 
Watson can be used to improve the efficiency of existing drug safety personnel and 
support timely reporting of AEs to regulatory agencies. 
Machine learning models pose risks when PV managers must justify the decisions 
made by the system in the event of a health agency inspection or an audit. PV managers 
must ensure they understand the implicit rules that the machine learning models use to 
make the decisions (Tomita, 2019). A combination of a machine learning approach and 
human review can be a potential effective and scalable solution for AE detection from 
social media (Comfort et al., 2018). Automated identification using machine learning 
models is a more efficient way to provide initial review of AEs and the human resources 
can be redirected to review and remedial actions more quickly to respond to emerging 
safety issues (Wang, Coiera, Runciman, & Magrabi, 2017). 
Negi, Pavuri, Patel, and Jain (2019) proposed a novel method of combining 
machine learning and NLP technology to assist with automating AE and suspect drugs 
extraction from medical reports. The first method tried to establish a causal relationship 
between the drug and the medical condition. The second method classified a drug into a 
suspect drug or a non-suspect drug using NLP features and machine learning for 
classification. Deep learning-based models and multi-task learning-based models can 
assist NLP in significantly improving the probability of identifying and extracting AEs 
from electronic health records (Li, Liu, & Yu, 2018). Most methods use annotated 
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datasets to predict AEs, neural nets, attention mechanisms, and multitask learning are 
popular choice for NLP applications for PV (Basile et al., 2019). Basile et al. (2019) 
noted that the use of machine learning and deep learning are common in academic 
research for PV but are not used in practice in the industry yet. 
Blockchain technology stores data in a list of securely linked blocks. Blockchain 
technology is currently widely used in the financial industry (Lewis & McCallum, 2019). 
Blockchain can be adopted for PV where the PV system is contained within a single 
protected environment. Lewis and McCallum (2019) envisioned a blockchain-based 
centralized PV system used by the various stakeholders in the future. 
Physicians can use innovative technology systems to predict an occurrence of AE 
before prescribing new medicines. Lee and Chen’s (2019) developed a machine learning-
based conceptual framework to predict the occurrence of AE which can benefit drug 
manufacturers, healthcare providers, and patients. Dynamic systems can be integrated 
into PV, thereby enabling predictive analytics and reasoning. However, due to the lack of 
regulatory guidance and problems with system validation, implementing and adopting 
dynamic intelligent systems is a challenge (Lewis & McCallum, 2019). 
Strategies for implementing innovative technology in PV. Regulatory agencies 
worldwide have improved and changed their safety monitoring processes, which has led 
to increased reporting requirements (Stergiopoulos et al., 2019). Due to the changing 
regulations for safety surveillance, MA holders in the pharmaceutical industry create new 
internal processes or include new data sources to detect AEs (Stergiopoulos et al., 2019). 
Multiple factors determine the successful implementation of innovative technology 
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including the approach and strategy, types of data, and change management. Alotaibi and 
Federico (2017) presented that the same technology used in different companies produce 
varied outcomes. Different kinds of data can be handled with different technology 
solutions like machine learning for unstructured data (Karimi et al., 2015).  
In their study focused on PV operational costs and drivers, Stergiopoulos et al. 
(2019) reported that several companies out of the 12 that participated in the survey had 
plans for including automation technology like machine learning. But none had 
implemented them as of 2018. Outsourcing was considered as one of the strategies for 
organizations to focus on the core competencies, reduce costs (Mishra et al., 2019), and 
eliminate internal resources. However, most companies are bringing PV operations back 
in-house due to operational inefficiencies and increased risks (Stergiopoulos et al., 2019).  
The impact of innovative technology solutions on the organizational structure and 
job profiles will be evident since the AI solution will replace certain manual processes. 
Beninger (2018) emphasized on the new skillsets, which will define the roles of the next 
generation of professionals who perform PV activities. Mesko et al. (2018) identified 
human resource crisis like accessibility and shortages in healthcare. Although Mesko et 
al. (2018) did not directly associate the resource problems to PV in the article, the authors 
concluded that the gaps in the human resource could be filled using advanced 
technologies like AI. Mesko (2017) strongly recommended that data analysis solutions 
must be implemented to support the skills of physicians and must not replace the 
traditional physician–patient relationship. Organizations must expect to supplement the 
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human workforce with expert systems and AI that can provide aggregated information for 
making decisions (Tomita, 2019). However, AI also raises ethical questions. 
Digital transformation includes alignment of technology with the company’s 
culture, people, structure, and tasks (Kiron, Kane, Palmer, Phillips, & Buckley, 2016). 
The human and technology relationship should also include user training, interaction, and 
collaboration sub-goals in order to be effective (Oyekan et al.,2017). While concluding 
that automation technology like deep learning can support with managing the AE 
volume, complexity, and time constraints of AE report processing, Routray et al. (2020) 
emphasized that human intervention will be required, and the technology must only 
augment human review of AE seriousness. Internal drivers of a company, specifically, 
organizational culture and environmental issues must be considered to leverage 
advantages of data analytics (Hawley, 2016). A smart, creative, and dynamic innovation 
culture will help organizations to see the value of invention (Keles & Battal, 2017). Ali 
and Khan (2019) identified two categories of assessing organizational readiness for 
implementing business intelligence: readiness of managerial proficiency and readiness of 
information systems environment. Mishra eta l. (2019) strongly recommended that 
organizations must setup a governance structure like center of excellence for the 
automation and digitization initiatives. 
AEs have increased exponentially over the years, and the processing and reporting 
impose substantial costs (Karimi et al., 2015; Schmider et al., 2018). Cost of 
implementing innovative technologies is high, which can be offset by savings post-
implementation (Mesko, Hetenyi, & Gyorffy, 2018). Automated identification can help to 
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find misidentified incidents and enhance data quality (Lewis & McCallum, 2019; Wang 
et al., 2017). Stergiopoulos et al. (2019) noted that all PV leaders believed implementing 
AI-based solutions will decrease costs for PV operations including simplifying AE 
detection and processing. Data mining, machine learning, AI, and robotics can be used to 
reduce costs and improve efficiency (Karimi et al., 2015; Lu, 2009; Schmider et al., 
2018). Therefore, pharmaceutical companies use technology increasingly to automate 
various tasks within PV. 
To enable adoption, PV managers must create a vision and project new 
technology as a product designed to create, attract, and satisfy demand (Gherasim, 2011). 
Creating mission statements is the first step in strategic management establishing 
objectives, formulating strategies, and communicating with the customers (David, David, 
& David, 2014). All stakeholders must provide endorsement and work toward making a 
digital future a reality. PV managers must ensure the technology solutions are aligned 
with the business needs and led by business operations (Mishra et al., 2019). Aligning 
business needs with IT governance and executive management IT competence had a 
strong and positive effect on innovation (Heroux & Fortin, 2018). Managers must 
implement technology solutions that improve employees’ job satisfaction by matching 
the task requirements and long-term professional needs (Wang, Wang, Zhang, & Ma, 
2020).  
Mishra et al. (2019) summarized that business process simplification, 
standardization, and re-engineering are the critical factors for a successful automation 
strategy. IT solutions alter business processes and existing work patterns leading to re-
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training and re-learning, which could increase employees’ work-related stress (Wang et 
al., 2020). Training and re-learning initiatives assist in preparing and guiding the in-house 
staff for digital transformation (Mishra et al., 2019) and to incorporate and blend RPA 
and AI bots in their daily job. This will assist in adoption of innovative technology by the 
employees. 
Social influence can be a moderating factor for both adoption and resistance of 
innovation. Social influence can reduce innovation resistance for inexperienced users 
potentially through usage (Matsuo, Minami, & Matsuyama, 2018). To enable adoption of 
innovative technology, which could change the role or even replace a human user, leaders 
much perform effective change management, which transforms the way people perceive 
innovative technology solutions.  
Transition  
The purpose of this qualitative single study was to explore the strategies used by 
PV systems managers to implement innovative technology solutions to automate AE case 
processing. I used the conceptual framework to understand the strategies provided by the 
participants to address the research problem identified in Section 1. In Section 1, I 
covered the key elements of the study including the problem statement, its purpose, 
research question, conceptual framework, and a review of literature. In Section 2, I 
provide justification for the selected research method and approach that was used for this 
study, including my role as the research instrument, the population, participants and 
sampling, data collection, analysis, and reliability and validity of the study. Upon 
approval from the IRB, I contacted my participants, collected the data, performed data 
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analysis, and then expanded this study to include the data analysis and findings. In 
Section 3, I describe the findings of the study, recommendations for future research, 




Section 2: The Project 
In this section, I discuss the design of this single case qualitative study by 
restating the purpose of this study and including the role of the researcher, participants, 
research method and design, population and sampling, ethical research, data collection, 
data analysis technique, and reliability and validity. 
Purpose Statement 
The purpose of this qualitative single case study was to explore the strategies that 
PV systems managers in the pharmaceutical industry use to implement innovative 
technology solutions to automate AE case processing. The target population consisted of 
four PV systems managers working in a pharmaceutical company located in the Boston 
area of Massachusetts, United States, who had used successful strategies to implement 
innovative technology solutions to automate AE case processing. The implications for 
positive social change include the potential to improve patient safety by identifying 
successful strategies that PV systems managers can use or adapt to implement innovative 
technology solutions to automate AE case processing. 
Role of the Researcher 
The researcher plays a critical role in conducting a research. The inquirer is the 
primary data collection instrument performing the data collection and analysis activities 
in qualitative research (Cypress, 2018). As the researcher, I conducted this qualitative 
single case study using interviews as the primary method to gather information. I served 
as the data collection instrument by enrolling participants and interviewing them using 
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open-ended questions and collecting and analyzing the data from the semistructured 
interviews.  
My employment in the pharmaceutical industry and the professional relationships 
I have established may have influenced the participants’ willingness and interest to 
participate in this study. I have interacted with other PV industry leaders and managers as 
a part of my professional engagement at my place of work. Though social relationships 
and personal contacts of the researcher can be leveraged, the researchers must build a 
respectful and trusting relationship with the participants and the relationship could lead to 
bias (Joseph, Keller, & Ainsworth, 2016). As the researcher, I ensured that data collection 
and analysis were objective by assessing the implications, as stated by Cypress (2018) 
and decreasing my personal views about the phenomenon in an attempt to minimize and 
mitigate bias and help achieve research integrity as recommended by Overgaard (2015). 
Because I was familiar with my research topic, I used bracketing during the research 
process by listing all my assumptions prior to data collection and including them as a part 
of the study data analysis to identify any potential bias. I used one of the many methods 
of bracketing to minimize bias. Reflective journaling as a method of bracketing can be 
used to identify researcher’s preconceptions toward the research topic before or during 
the research process (Tufford & Newman, 2010). I used reflective journaling as a method 
to identify my assumptions regarding the research since I worked in the PV systems 
function in a pharmaceutical company. Triangulation strategy is used to reduce risks and 
remove systemic bias (Cypress, 2018). I used multiple data collection methods like 
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semistructured interviews, documents and presentations, and the reflective journal to 
facilitate triangulation. 
I used semistructured interviews to understand the strategies that the PV managers 
use to implement innovative technologies. Interviews provide a more complete picture of 
the phenomenon by reconstructing and interpreting the past (Cypress, 2018). Good and 
actionable questions are used to gather rich and deeper understanding of the issues and 
events (Jonsen, Fendt, & Point, 2017). In order to regulate the interview procedure and 
maintain control (Leonidaki, 2015) and enable consistency and inform participant about 
their rights (Castillo-Montoya, 2016), I established an interview protocol (Appendix A) 
to conduct the interviews. I captured notes and audio recorded the interview upon 
receiving consent from the participants. I requested additional documents from the 
participants and reviewed any publicly available information. I transcribed the 
information gathered and subjected it to triangulation and member checking.  
I used the Belmont Report to guide my ethical behavior during this study. The 
Belmont Report focused on three ethical principles and their applications to conduct 
research. Informed consent, risk/benefit assessment, and selection of subjects of research 
requirements cover the principles-respect for persons, beneficence, and justice (National 
Commission for the Protection of Human Subjects and Biomedical and Behavioral 
Research, 1979). I adhered to the three principles by using confidentiality procedures to 
protect the participants and maintain privacy. By explaining the study objective, the 
interview process, the use of data collected, and obtaining informed consent, I mitigated 
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ethical issues as recommended by Cypress (2018). I will store the data collected in a 
password-protected flash drive and duly discard after 5 years.  
Participants 
I purposively selected a pharmaceutical company in the Boston area of 
Massachusetts, United States as the single case for this study. Qualitative studies that aim 
to explain a phenomenon in a specific context tend to use a purposive sampling design 
(Sovacool, Axsen, & Sorrell, 2018; Tobi & Kampen, 2017). The primary criteria for 
selecting the participants for this single case study included systems managers in the PV 
or Safety department related to the PV Systems function employed in the selected 
company. The participants were involved in successfully developing and implementing 
innovative technology strategies to automate AE case processing and were willing to 
participate in this study.  
Researchers must gain access to the qualified individuals who must be willing to 
participate in the study (Peticca-Harris, deGama, & Elias, 2016). I obtained authorization 
from Walden University’s Institutional Review Board (IRB). Walden University’s 
approval number for this study is 04-24-20-0972741 and it expires on April 23, 2021. 
The number of participants depend on the characteristics of population from which they 
are chosen (Saunders & Townsend, 2016). I identified eligible and qualified employees 
for this study prior to inviting them to participate.  
The relationship between the researcher and the participant is crucial. The 
participants must be at ease to respond honestly to the questions, therefore, building trust 
and establishing a respectable relationship are imperative (Malterud, Siersma, & 
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Guassora, 2016; Yin, 2018). To build the relationship, I followed the best practices 
suggested by Yin (2018) for credible qualitative research. I explained the objective and 
the process of the study to the participants and obtained their willingness to participate. I 
established a professional working relationship with the participants by talking to them 
over the phone and maintaining confidentiality. 
Research Method and Design  
The research method and design define the intention of the study and represent 
the characteristics of the proposed research. In addition, the method and design connect 
the study with the procedures for data collection and data analysis processes (Ward, 
Comer, & Stone, 2018). Research methodology impacts theory development, the 
analysis, research duration, and the outcomes of the research (Saunders et al., 2015). In 
this section, I justify the reasons for deciding to conduct a qualitative case study to 
explore the strategies used by PV systems managers to implement innovative technology 
solutions for AE case processing automation.  
Research Method 
A research method guides the investigators to obtain answers to the research 
question while ensuring rigor in the research and reliability of results (Dresch, Pacheco 
Lacerda, & Cauchick Miguel, 2015). There are three types of research: qualitative, 
quantitative, and mix-methods research (Yin, 2018). During the research for a 
methodology, I considered all the three types of research. Upon detailed research, I 
decided to conduct a qualitative study to explore the strategies managers use to 
implement innovation technologies. 
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The primary purpose of my study was exploration, with a pursuit of identifying 
strategies to address my research question. Exploratory studies allow researchers to 
understand an issue, a problem, or a phenomenon (Saunders et al., 2015). Qualitative 
studies focus on phenomena based on ideas related to human knowledge, including an 
objective to share knowledge and extend research data (Ward et al., 2018). Using a 
qualitative method, the researcher can understand a phenomenon through a participant’s 
perspective based on rich data and thick descriptions (Azungah, 2018; Barnham, 2015). 
Using the qualitative approach, researchers can gain an understanding of reasons behind a 
phenomenon using an open-ended, exploratory stance, instead of proving or disproving 
hypotheses (Taguchi, 2018). A qualitative approach can be valuable in case of novel 
questions in business where there is less data or where little or no theory exists to deduce 
research hypothesis (Reinecke, Arnold, & Palazzo, 2016). Therefore, a qualitative 
approach was an appropriate methodology for this study. 
Developing generalizable rules and verification or falsification of hypotheses are 
the focus of quantitative research methods (House, 2018). Researchers collect numerical 
data in order to test theories or hypotheses using measurement of specific variables 
(Saunders et al., 2015). The research problem and question of my study did not require 
testing correlations, hypotheses, or existing theories using statistical analysis or 
mathematical models. Therefore, a quantitative approach was not suitable for this study. 
Researchers use mixed method research when their research question can be best 
answered by an integrated qualitative and quantitative research than either of them alone 
(House, 2018; Saunders et al., 2015). Challenges of mix method include the large amount 
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of time the study requires, size of samples, and quality of data and related interpretation 
during analysis (House, 2018). Mixed method is complicated and is discouraged for 
students (Fusch et al., 2018). Though a mixed method approach may have fit my research 
problem, required sample size, large amount of time, and potential for discrepancies 
during analysis were major deterrents.  
Research Design 
A research design is a plan to collect and analyze data in order to obtain answers 
to the research question to maximize validity and efficiency (Palinkas et al., 2015). Case 
study, ethnography, and phenomenology are the common qualitative research designs. 
Research questions pertaining to the understanding of organizational processes can be 
best addressed using a case study approach (McIntosh & Morse, 2015). The two main 
purposes of case study are exploration and theory-building (Runfola, Perna, Baraldi, & 
Gregori, 2017). A case study is used to identify what decisions that were made, why, and 
how they were implemented which yielded certain results (Yin, 2018). Using a case study 
strategy enables researchers to perform in-depth inquiry into a topic to generate insights 
in a real-life context experiences (Saunders et al., 2015; Yin, 2018). A case study focuses 
on how things are and how they behave (Dresch et al., 2015). Case study facilitates 
collecting richer information pertaining to a phenomenon (Dasgupta, 2015). 
Semistructured interviews can assist in ascertaining participants’ perspectives of their 
experiences related to the study topic (McIntosh & Morse, 2015).  
A researcher selects a case study design to explore a smaller sample using 
multiple approaches to gather data (Dresch, Pacheco Lacerda, & Cauchick Miguel, 2015) 
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and conducts investigation and builds theories where the phenomenon is newer or poorly 
understood (Runfola et al., 2017). A case study design can be conducted on a single case 
or multiple cases. A single case study design is appropriate when researching a unique 
case (Dasgupta, 2015). Multiple case design allows researchers to build theories by 
proving a strong base for cross case analysis (Yin, 2018). A single case study design was 
deemed more appropriate to explore strategies used by some PV managers to implement 
innovative solutions for automation.  
Case studies are more common (Sovacool et al., 2018) and popular than the other 
qualitative research designs like phenomenology and ethnography. Phenomenology is 
concerned about a less known lived experience (Lewis, 2015), whereas a case study 
focuses on a phenomenon to be studied in the environment it takes place (Tobi & 
Kampen, 2017). Researchers conduct phenomenological studies to analyze lived 
experiences. Because my study focused on strategies used for implementation of 
automation solutions, and not on lived experience of an employee, phenomenology was 
not an appropriate design. The purpose of ethnography is exploration of a phenomenon in 
a cultural context (Lewis, 2015). Because cultural context was not critical for my study, 
ethnography was not a suitable design.  
Data saturation is an important aspect of qualitative case studies. Data saturation 
is reached when no new information or themes are observed and the information can be 
used to replicate the study, making it capable of generalization (Fusch & Ness, 2015; 
Saunders et al., 2017). The depth and richness of data will determine the data saturation 
and not solely the sample size of the population (Boddy, 2016; Fusch & Ness, 2015). I 
54 
 
ensured I collected in-depth information and rich and thick descriptions and continued the 
interview process until no new information was discovered. I used member checking as 
recommended by Fusch and Ness (2015) to achieve data saturation. 
Population and Sampling 
The study population is the total number of people within the organization eligible 
for sampling consideration in the interview study (Yin, 2018). To fit the purpose of the 
study and collect relevant knowledge, researchers following qualitative approach use 
specific criteria to purposively sample participants (Lewis, 2015; Sovacool et al., 2018). 
The target population for this single case study consisted of PV systems managers who 
were involved in successfully implementing innovative technology strategies to automate 
AE case processing and employed in the selected pharmaceutical company in the Boston 
area of Massachusetts, United States. The participants were willing to participate in this 
study. 
Because this study is set in a specific function within a pharmaceutical industry, a 
purposive sampling design was used to select participants for this study. A purposive 
sampling design is used when a particular phenomenon is studied in a specific context 
(Tobi & Kampen, 2017; Yin, 2018). The participant sample must be representative of the 
population (Boddy, 2016). The sampling technique did not yield a large and diverse 
selection of participants from the PV function of a small pharmaceutical company. 
Therefore, I invited four PV systems managers to participate in the study.  
To decide the number of participants to be interviewed for this study, I followed 
the principles of data saturation. Data saturation is reached when no new information or 
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themes are observed and the information can be used to replicate the study, making it 
capable of generalization (Fusch & Ness, 2015; Saunders et al., 2017). The number of 
participants for a study is contingent on the population chosen (Saunders & Townsend, 
2016). The depth and richness of data will determine the data saturation and not solely 
the sample size of the population (Boddy, 2016; Fusch & Ness, 2015).  
I interviewed four PV systems managers, selected using the purposive sampling 
method. In their qualitative study, Palaya, Pearson, and Nash (2018) conducted eight 
interviews since the authors could not find additional participants matching the 
participation criteria. Morley (2020) recruited and interviewed four participants for her 
study. Kawano (2017) interviewed two sets of three participants each for her qualitative 
study. Since no standards for sample size exist for qualitative studies (Malterud, 2016), 
sample size for qualitative studies are varied, driven by data saturation. Also, since my 
study participation criteria did not yield many participants, I interviewed four PV systems 
managers working in a single pharmaceutical company.  
I obtained authorization from Walden University’s IRB using which, I obtained 
consent from potential candidates to participate. Walden University’s approval number 
for this study is 04-24-20-0972741 and it expires on April 23, 2021. I contacted the study 
participants by phone or email requesting their participation in the study and their 
response indicating their willingness to participate was documented. Quantitative 
interviews provide rich descriptions of complex organizational realities and offer 
ecological validity (Saunders & Townsend, 2016). The interview protocol and the 
interview questions as shown in the appendix A were administered to the participants via 
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telephonic interviews. I digitally audio recorded and transcribed the interviews to 
facilitate reliability of the data. Reliability is also ensured through member checking, 
which is the process of involving the participants in the interpretation of data to enhance 
the credibility of the results (Birt, Scott, Cavers, Campbell, & Walter, 2016). The 
participants were asked additional questions if needed to confirm accuracy and obtain any 
additional information or potential correction of data (Birt et al., 2016; Morse, 2015). 
Member checking follow-up interviews were originally planned to be conducted if 
required, to assist with interpretation of the transcripts. However, analysis and 
interpretation of the transcripts did not require follow-up interviews.  
Ethical Research 
All research, regardless of methodology and context, face various ethical issues 
when focusing on human experience needs, actions, and beliefs (Islam, 2019). Methods 
of access, informed consent, conflict of interest, research design, relationship with the 
participants, and understanding of contextual risks contribute to ethical concerns 
(Wallace & Sheldon, 2015). I used confidentiality procedures to protect the participants 
and maintain their privacy by following the protocols defined in the Belmont report 
(National Commission for the Protection of Human Subjects and Biomedical and 
Behavioral Research, 1979). To ensure adherence to the ethical standards, I obtained 
approval from Walden University’s IRB. Walden University’s approval number for this 
study is 04-24-20-0972741 and it expires on April 23, 2021. 
Consent is a combination of the form or document and communication with the 
participants as a part of the conversation (Wall & Pentz, 2016). I used the consent form 
57 
 
and held an informed consent conversation prior to the interview to ensure the 
participants understood the key elements and their rights pertaining to informed consent 
as a recommended best practice by Koyfman, Reddy, Hizlan, Leek, and Kodish (2016). 
The consent process must include the privacy and confidentiality protection (Ennever, 
Nabi, Bass, Huang, & Fogler, 2019). I provided a student participant invitation and 
informed consent form to all participants and obtained their consent to participate prior to 
data collection. The participants had the right to withdraw from the study at any point 
before and during the interview process and were asked to communicate their withdrawal 
via email or by refusing to answer the interview questions and exit at any time. 
Participation in this study was voluntary and no incentives were offered.  
I conducted telephonic interviews by following the interview protocol and 
questions (Appendix A). I followed the same protocol to interview all participants. I 
digitally recorded the interviews after obtaining consent from the participants. To protect 
the rights of the participants, I will store the data collected as password-protected files on 
a flash drive for 5 years. After 5 years, I will duly destroy the data collected including the 
recording files and any documents. To ensure confidentiality, I did not use the 
participants’ names, organization name, or any identifiable information as a best practice 
recommended by Ennever et al. (2019) and instead, assigned codes such as P1 and P2 to 
the participants to ensure participant privacy. This study was voluntary. There was no 
payment for participation.  
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Data Collection Instruments  
The researcher is the primary data collection instrument performing the data 
collection and analysis activities in qualitative research (Cypress, 2018; Houghton, 
Murphy, Brooker, & Casey, 2016). Qualitative researchers must begin to be reflexive and 
must consider the ethicality of their methodology (Thurairajah, 2019). As the researcher, 
I conducted this qualitative single case study using interviews to gather information. I 
served as the data collection instrument by enrolling participants and interviewing them 
using open-ended questions and collecting and analyzing the data from the 
semistructured interviews.  
The interview protocol (Appendix A) was used to conduct interviews and collect 
data. Using a protocol ensured that the important aspects of the research questions from 
the literature review were included in the interview (Azungah, 2018). Interview questions 
for data collection covered important concepts of interest, which as suggested by Yin 
(2018), provided a direction for data analysis. The quality of the interview protocol 
impacts the study (Zhu & Mostafavi, 2017). The interview protocol (Appendix A) 
contained multiple sections including an introduction and the list of questions developed 
from the important aspects of the research question. I started with explaining the 
background and the objective of the study, included the confidentiality statements, and 
reminded the participants about withdrawal as defined in the protocol.  
Interviews are a primary source of data for qualitative case studies (Runfola et al., 
2017; Yin, 2018). I used semistructured interviews guided by the interview protocol to 
collect data to explore strategies used by PV systems managers to implement innovative 
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technology solutions for automation. I included multiple sources of data to determine 
convergent or divergent findings (Reinecke et al., 2016). Multiple sources of data like 
interviews, reflective journals, or documents promote study validity via triangulation 
(Morse, 2015; Yin, 2018). I searched for publicly available information like 
announcements or presentations and additionally requested the participants for 
documents they will be willing to share after the interview. I called the participants on 
their preferred phone number at an agreed time. I obtained participant consent to audio 
record the interview. To ensure data accuracy and reliability, I initiated the member 
checking process and triangulation. Member checking or participant validation is the 
process where the participant is involved in the interpretation of the data and is asked 
additional questions during and after the interview to confirm accuracy and obtain any 
additional information or potential correction of data (Birt et al., 2016; Morse, 2015). I 
shared my interpretations with the participants and requested approval or corrections as a 
part of member checking process. All participants confirmed accuracy and one 
participant responded with minor corrections. The final versions of the transcript and 
interpretation was used for data analysis. 
Data Collection Technique 
To explore strategies that PV systems managers used to implement innovative 
technology solutions for automation, I collected data directly from the PV systems 
managers in the form of interviews and additional documents. Yin (2018) identified four 
principles of data collection to ensure high-quality case studies: use multiple sources of 
evidence, a case study database, maintain a chain of evidence, and exercise care using 
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electronic sources of evidence. The primary data collection technique I used is telephonic 
semistructured interviews guided by the interview protocol (Appendix A). In addition, I 
reviewed any publicly available information or presentation and documentation shared by 
the participants related to this study. Interviewing, field observations, and document 
analysis are the primary methods of data collection in qualitative studies (Chenail, 2011). 
I obtained approval from Walden University IRB prior to interviewing the participants. 
Walden University’s approval number for this study is 04-24-20-0972741 and it expires 
on April 23, 2021. To focus on a particular phenomenon, I used the purposive sampling 
design recommended by Tobi and Kampen (2017) to identify participants. I called the 
participants at a predetermined time to conduct interviews. I shared the informed consent 
form, reviewed the content of the form, and requested an email response confirming 
willingness to participate in the study. Upon receiving permission from the participants, I 
audio recorded the interviews using the voice recorder application installed on my 
Samsung mobile phone. To enable consistency, maintain order, and ensure the 
participants understand their rights, I used the interview protocol as a guide (Castillo-
Montoya, 2016). The same interview protocol was used with all the identified 
participants to ensure consistency. Since reflective journaling can be used to improve 
critical thinking and problem solving (Taliaferro & Diesel, 2016), I captured notes and 
used reflective journaling approach and made notes to gain insight into events described 
by the participants. 
The use of semistructured interview approach allows the researcher to ask open-
ended questions (Yin, 2018) and facilitate open interaction with the participants so they 
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can provide rich data and thick descriptions. Interviews can be targeted to focus on a 
specific topic and well-informed interviewees can offer credible insights. However, as 
noted by Yin (2018), interviews are subject to problems of bias, inaccurate articulation, 
and poor recall. To mitigate the problems, I shared the interview questions ahead of the 
interview so the participants could collate the information and formulate their responses. 
I transcribed the recorded interviews, and the transcripts and the interpretations 
were shared with the participants to confirm accuracy and enhance validity by achieving 
data saturation. Data saturation is achieved when no new information or themes are 
observed and the information can be used to replicate the study (Fusch & Ness, 2015; 
Saunders et al., 2017). Data saturation is critical to establish study validity (Morse, 2015). 
Member checking and follow-up member checking interviews can also assist in reaching 
data saturation (Yin, 2018). I included my assumptions and bias identified in my 
reflective journal during the transcription of the interviews, with the objective of 
surfacing any additional questions or clarifications to pursue as a part of follow-up 
interviews. During the transcribing and interpretation, I did not have any additional 
follow-up questions. All participants confirmed accuracy and one participant responded 
with minor corrections. I had originally planned on conducting member checking follow-
up interviews or email correspondences and edit the transcripts and interpretations 
accordingly until data saturation was achieved. However, I did not need to conduct any 
follow-up interviews and I was able to achieve data saturation. 
In addition to providing answers to interview questions, I requested participants 
for any documentation to corroborate the data. Documents such as standard operating 
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procedures, policies, and best practices can help discover underlying themes (Yin, 2018). 
Documents are stable and can corroborate evidence from other sources (Yin, 2018). Yin 
(2018) also added that document review could result in contradictory evidence and the 
findings might not corroborate with collected data, which can result in further 
investigation. I triangulated the analysis of the documents received from the participants 
and those publicly available and the interview data. Triangulation is a process of 
authenticating information using multiple sources of data or methods concerning the 
same event to decrease bias and increase validity of the study (Fusch et al., 2018; Joslin 
& Müller, 2016). By performing triangulation and member checking, I created an 
advantage for myself as the researcher to attempt to reduce bias and enhance the validity 
and reliability of this study. 
Data Organization Technique  
To achieve the objectives of this study and ensure I conduct a high-quality study, 
the following information was collected for this study: audio recording of every 
semistructured interview captured via mobile phone, notes and journal entries, 
transcriptions of the interviews, informed consent, reflective journal, project documents 
and presentations regarding the innovative technology implementation as shared by the 
participants. I had requested the participants for any project documents, public 
presentations, procedures, policies, and best practice documents, and internal 
communications. I collected the aforementioned documents and files electronically and 
will store in a password protected flash drive for 5 years. I had planned to convert any 
hard copies into electronic format to be able to store them digitally, after which the hard 
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copies will be returned to the participants or destroyed by shredding. However, I did not 
receive any hard or paper copies. I used ATLAS.ti software to organize the collected data 
and maintain a list of codes and keywords, including bias from my reflective journal to 
compile, disassemble, reassemble, interpret, and conclude the findings. In addition, I 
established a case study database as recommended by Yin (2018) to track all the data 
collected and maintain a chain of evidence. To ensure confidentiality and protect the 
participants from harm, I refrained from using the participants’ names as recommended 
by Ennever et al. (2019) and Wall and Pentz (2016) and instead, assign codes such as P1 
and P2 to ensure participant privacy. A few participants identified names of the 
organization during the interview. To maintain participant privacy, I removed all 
occurrences of their names or the organization names while transcribing. I labeled the 
data collected from the participants per the assigned codes. All the collected data will be 
stored for 5 years after the completion of the study and duly destroyed after.  
Data Analysis  
Organizing the collected data and identifying realistic meaning and drawing 
conclusions is the purpose of performing data analysis (Bengtsson, 2016). To enhance the 
validity and reliability of my study and ensure data saturation, I performed triangulation 
and member checking. Triangulation is a process of authenticating information using 
multiple sources of data or methods concerning the same events to decrease bias and 
increase validity of the study (Fusch et al., 2018; Joslin & Müller, 2016). Methodical 
triangulation involves multiple methods of data collection to view a phenomenon (Fusch 
et al., 2018; Sovacool et al., 2018; Yin, 2018). I used methodical triangulation approach 
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and triangulate the data I collected from the interviews, internal and publicly available 
company and project documentation as evidence of strategies the PV systems managers 
used to implement innovative technology solutions for automation. The constructs of the 
TTF model and the research question assisted in focusing the data analysis on the themes 
identified from the literature review. 
Based on Yin’s (2018) recommended five-step data analysis, I used the ATLAS.ti 
software to compile, disassemble, reassemble, interpret, and conclude the findings. I 
transcribed the data. After confirmation of accuracy from the participants, I used the final 
version of the transcripts and interpretation for data analysis. I performed content analysis 
by identifying themes and patterns in ATLAS.ti. The objective of content analysis is to 
systematically identify themes and patterns by coding of interview transcripts and 
documentation (Sovacool et al., 2018). I had identified a list of codes from my literature 
review as my initial set of codes for analysis. I also included my assumptions and biases 
recorded in my reflective journal for coding in ATLAS.ti software for data analysis. This 
process assisted in successfully performing bracketing and the researcher bias was 
included while performing content analysis. ATLAS.ti software assisted in organizing the 
collected data, maintaining a list of codes and keywords to maintain consistency 
(Bengtsson, 2016; Yin, 2018), and identifying themes. I established a case study database 




Reliability and Validity  
Reliability 
Researchers must be methodical in order to establish rigor and ensure reliability 
of their findings. Reliability refers to replication or repeatability to achieve consistent 
findings (Bengtsson, 2016; Yin, 2018). To ensure dependability, repeatability, and 
consistency during data collection, I used an interview protocol with a set of interview 
questions (Appendix A) and administered the same protocol to all the participants. 
Reliability can be achieved by designing a well thought out, consistent research process 
by promoting stability while coding and analyzing the data, and being transparent with 
reporting (Saunders et al., 2015). Despite being an efficient way of collecting data, 
interviews can be biased, which can affect the reliability of the study (Runfola et al., 
2017). An unreliable research will be invalid since errors or bias will affect the findings, 
the analysis, and the interpretation (Saunders et al., 2015). Strategies to ensure reliability 
included using a coding system, member checks, thick description, and triangulation 
(Morse, 2015). 
Validity 
Validity refers to appropriateness of measures, accuracy of analysis, and 
generalizability (Saunders et al., 2015) that truthfully and accurately describes the 
phenomena (Bengtsson, 2016). Validity refers to the credibility, transferability, and 
confirmability of the findings. A study is credible when the results presented with the 
context are recognizable to people who share the experience, which refers to truthfulness 
or the internal validity of the study (Hammarberg, Kirkman, & de Lacey, 2016). 
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Transferability is the extent to which the study findings are useful to other people, which 
is achieved by researchers being transparent (Connelly, 2016). Confirmability refers to 
the degree to which a study is consistent and can be repeated (Connelly, 2016). Validity 
is one of the prime concerns of researchers using qualitative methodology (Fusch et al., 
2018). The subjective nature of unstructured data collection poses a threat to validity 
(Morse, 2015). To determine validity, Morse (2015) identified prolonged engagement, 
peer review, negative case analysis, using a coding system, member checking, 
triangulation, etc. Data saturation is important to establish validity and is reached when 
there is enough information to replicate the study and there is no additional new 
information (Fusch & Ness, 2015; Saunders et al., 2017). 
I used two techniques to establish reliability and validity in this study: (a) 
triangulation which is a process of authenticating information using multiple sources of 
data or methods concerning the same phenomenon to decrease bias and increase validity 
of the study (Fusch et al., 2018; Joslin & Müller, 2016). (b) member checking or 
participant validation: the process where the participant in involved in the interpretation 
of the collected data and is questioned during the interview process to confirm accuracy 
and obtain any additional information or potential correction of data (Birt et al., 2016; 
Morse, 2015). I used both triangulation and member checking as methods to reach data 
saturation. Data saturation is reached when no new information or themes are observed 
and the information can be used to replicate the study, making it capable of 
generalization (Fusch & Ness, 2015; Saunders et al., 2017). Data saturation refers to the 
depth of the data (Fusch & Ness, 2015). I ensured I collected in-depth information and 
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rich and thick descriptions and continued the interview process until no new information 
was discovered. I used member checking as recommended by Fusch and Ness (2015) to 
achieve data saturation. 
I gathered rich data and thick descriptions and documentation during the 
interviews (Sovacool et al., 2018) to allow for transfer of the study findings to another 
context, thereby increasing credibility. I shared the interview transcripts and my 
interpretation with the participants to review and confirm the accuracy of the transcripts 
and my interpretation of the events. To increase confirmability, I included my 
assumptions and bias identified in my reflective journal during the transcription of the 
interviews, with the intention of surfacing any additional questions or clarifications to 
pursue as a part of follow-up interviews. I also included my assumptions and bias during 
data analysis to perform bracketing and assist with mitigating bias. To ensure 
confirmability and data saturation, member checking was conducted until no new 
information emerged. However, I did not conduct follow up interviews. I triangulated the 
information gathered from the interviews with the documentation to further confirm data 
saturation. To increase the reliability of the study, I established a case study database as 
recommended by Yin (2018) to track all the data collected and maintain a chain of 
evidence. I addition, I maintained an audit trail and recorded the approach for the data 
collection, interpretation, and analysis to enable retracing of the steps and duplication, 
thereby increasing transferability. 
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Transition and Summary 
The purpose of this qualitative single study was to explore the strategies used by 
PV systems managers to implement innovative technology solutions to automate AE case 
processing. In section 2, I provided justification for selecting qualitative single case 
design for this study and focused on the strategies and approaches used for key 
components of this study. I explained the research method and design, population and 
sampling of participants, my role as the research instrument, and my approach for ethical 
research, data collection instruments and techniques, data organization techniques, data 
analysis, reliability, and validity that were used for this study. Upon approval from the 
IRB, I collected the data, performed data analysis, and then expanded this study to 
include the data analysis and findings of this doctoral study. In the next section, I 





Section 3: Application to Professional Practice and Implications for Change 
Introduction 
The purpose of this qualitative single case study was to explore the strategies that 
PV systems managers in the pharmaceutical industry use to implement innovative 
technology solutions to automate AE case processing. I used a purposive sampling 
technique to select four PV systems managers working in a pharmaceutical company 
located in the Boston area of Massachusetts, United States, who have used successful 
strategies to implement innovative automation technology solutions for AE case 
processing. I collected data from semistructured interviews, conducted using an interview 
protocol (Appendix A) until data saturation was reached, and triangulated the data with 
documents collected from the participants.  
Three themes with nine strategies emerged during data analysis. The themes were 
(a) automation solution selection and implementation strategies, (b) business operational 
model changes, and (c) communication and training strategies. Internal drivers like 
vision, objectives, timelines, cost, and compliance; ensuring solution is fit for purpose; 
open communication, collaboration, and engagement; strong project management; and 
simplified, standardized, and efficient business processes emerged as the key strategies 
from these themes. The organization had contracted an external vendor to build a 
strategic long-term partnership for their PV database, which was their foremost selection 
and implementation strategy. The findings supported the existing findings on strategies 
from the academic literature review. In the next sections, I will present the study findings, 
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application to professional practice, implications for social change, recommendations for 
action, recommendations for further research, reflections, and conclusion.  
Presentation of the Findings  
In this study, I focused on the strategies that PV systems managers use to 
implement innovative technology solutions to automate AE case processing. I conducted 
semistructured interviews to collect data from four PV systems managers from a 
pharmaceutical company in the Boston area of Massachusetts, United States. I used the 
TTF model as the conceptual framework to guide my research on identifying the 
strategies PV systems managers use for automating PV case processing.  
Lai (2017) noted that the TTF model is suitable for investigating the utilization of 
new technology solutions. Therefore, the constructs of the TTF model were used as the 
conceptual lens to identify the strategies from the collected data. I used ATLAS.ti 
software to organize and analyze the data collected from the interviews. I manually 
analyzed the documents collected from the participants for document review. For initial 
analysis, I used word cloud for a visual representation of word frequency to get the first 
look and summarize the interview transcripts. The word cloud showed system, project, 
vendor, automation, implementation, communication, change, issues, and users as the 
key and most frequently used words by participants in the interviews as shown in Figure 





Figure 4. Word cloud showing the most frequently used words in the interview data. 
Created from ATLAS.ti. 
The organization had contracted an external vendor to build a strategic long-term 
partnership for their PV database, which was their foremost selection and implementation 
strategy. The following key themes emerged with detailed analysis of the interview data: 
(a) selection and implementation strategies, (b) business operational model changes, and 
(c) communication and training strategies.  
The automation solution selection and implementation strategies theme included 
five key strategies: internal drivers like vision, objectives, timelines, cost, and 
compliance; ensuring solution is fit for purpose; strong project management; strategic 
partnership with an external vendor; and defined metrics to measure effectiveness of the 
solution and project. Business operational model changes theme included two strategies: 
Simplified, standardized, and efficient business processes by supplementing and reducing 
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operational workforce and changes to organizational structure and job profiles. 
Communication and training strategies included open communication, collaboration, and 
engagement and training. The three main themes and the nine key strategies are shown in 
Table 2 below. The references coded refers to the number of times the data references 
were coded to the strategies. 
Table 2 
 










Internal drivers like vision, objectives, timelines, 
cost, and compliance 
18 
Ensure solution is fit for purpose 18 
Strong project management with a defined plan, 
dedicated resources, and stakeholders 
16 
Strategic partnership with an external vendor 14 
Defined metrics to measure effectiveness of the 




Simplified, standardized, and efficient business 
processes by supplementing and reducing 
operational workforce 
15 





Open communication, collaboration, and 
engagement with stakeholders incl. end users 
and vendor 
17 





Theme 1: Selection and Implementation Strategies 
Automation solution selection and implementation strategies was one of the key 
themes that emerged from the interview data. I analyzed the data in two steps, initial and 
detailed analysis. Initial analysis of the word cloud created by ATLAS.ti included vendor, 
system, project, time, implementation, automation, and communication as the key words 
as shown in Figure 5.  
 
Figure 5. Word cloud for selection and implementation strategies in the interview data. 
Created from ATLAS.ti. 
The word cloud for automation solution selection and implementation strategies 
reflected the strategies identified in the analysis of data. The leaders of the PV 
organization decided to strategically engage with an external vendor to supply the 
automation solution and implement the same. Managers have multiple options to 
implement technologies and value propositions and adopt a leader or follower strategy in 
the digitization arena (Ritter & Pedersen, 2019). This organization adopted the leader 
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strategy for automation. P4 indicated that the company was the first to implement this 
intake automation solution from the vendor. The following five key strategies emerged 
for selection and implementation strategies from the interview data: 
Internal drivers like vision, objectives, timelines, cost, and compliance. All 
participants identified internal drivers as one of the important strategies to guide the 
selection and implementation of automation solutions for AE case processing. The 
participants identified multiple internal drivers or factors like organization vision and 
objectives for automation, tight timelines, cost, and competing priorities while ensuring 
regulatory compliance. P1 and P2 stated that the PV organization created a long-term 
vision to leverage automation as much as possible to build efficiencies within PV 
business operations. In addition, P2 stressed on selecting a vendor who had a long-term 
vision and were invested in building and supporting the product. All participants 
identified tight timeline and P1 and P3 listed cost and capabilities as key internal drivers 
in addition. All participants stressed on staying compliant with regulations to process 
AEs and building a validated, compliant system. 
Ensure the solution is fit for purpose. All participants unanimously identified 
the fit of the automation solution to effectively perform as expected and match the tasks 
and constraints as a key strategy. P2 and P4 identified technical constraints like the 
solution platform must be on the Cloud and be compatible with the newly implemented 
PV database. Certain tasks which were performed manually were now replaced by a 
tactical automated solution. Therefore, the solution must be a fit for the tasks that needed 
to be performed, only more efficiently. Though the team had challenges with the solution 
75 
 
functioning as expected initially, they overcame the issues by leveraging the partnership 
with the vendor using collaboration and adjusting the business process and the solution to 
find an acceptable compromise. 
Strong project management with a defined plan, dedicated resources, and 
stakeholders. The project team consisted of internal employees and the external vendor 
team members. To successfully execute the project, a strong project management 
function was led by an internal temporarily contracted project manager to track the 
project and manage stakeholder engagement. To ensure the milestones and deliverables 
were met as defined in the project plan, a structured project plan was built, and dedicated 
resources and stakeholders were identified. All participants indicated strong project 
management and leadership as a key strategy. 
Strategic partnership with an external vendor. Because the automation 
solution was sourced and implemented by an external vendor, the PV systems managers 
decided to strike a strategic partnership with the vendor selected after a rigorous vetting 
process. Participants shared the realization that being a small pharmaceutical company, 
they did not have the relevant expertise inhouse. Therefore, PV management decided to 
build a strategic partnership with an external vendor who can source the automation 
solution and implement it. In addition, P2 stressed on partnering with a vendor with a 
vision who was invested in the technology and the solution for a long term. P4 
recommended having vendor support onsite during “go-live” though the vendor was 
offshore and implementation project was executed remotely. Participants summarized 




Defined metrics to measure effectiveness of the solution and the project. The 
PV leaders built multiple metrics to measure the effectiveness of both the automation 
solution and the execution of the project. To ensure the solution was fit for purpose, 
before and after metrics measuring the time and resources were built. All participants 
indicated that the metrics measured the amount of time taken to create and process AEs 
before and after the automation solution was implemented. To ensure the project matched 
the internal drivers, the project was closely monitored to ensure all the milestones were 
achieved. 
Documents provided by the participants showed automation, business process 
improvements, elimination of nonvalue-added activities, and metrics were the key 
internal strategies of focus. The documents also indicated strong leadership, open 
communication, and collaboration as key strategies for successfully implementing 
automation solution for AE case processing. Technical limitations like multitenant cloud 
implementation and adopting ISP configuration were included as internal drivers. The 
document review revealed timeline as an internal driver, as mentioned by all the 
participants in their interviews.  
The findings matched the academic literature review. PV managers must create a 
vision and project new technology as a product designed to create, attract, and satisfy 
demand (Gherasim, 2011). Though many companies automate many steps in the PV 
process, plenty of opportunities exist to make PV agile and efficient (Ghosh et al., 2020). 
Organization leaders have realized that proactive external collaboration is beneficial for 
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creation of new products and solutions (Di Fiore et al., 2017). Therefore, the PV 
leadership decided to partner with an external vendor. PV managers must ensure the 
technology solutions are aligned with the business needs and led by business operations 
(Mishra et al., 2019). Managers must improve employees’ job satisfaction and solution 
adoption by implementing IT solutions that fit the tasks and employees’ long-term 
professional needs (Wang et al., 2020). Internal drivers of a company, specifically, 
organizational culture and environmental issues must be considered to leverage 
advantages of data analytics (Hawley, 2016). Automation can support human workforce 
in managing the increasing AE volume, complexity, reporting timelines, and increasing 
efficiency, consistency, and compliance (Routray et al., 2020). Companies typically 
measure the benefits of automation in terms of quality, compliance, and efficiency 
(Ghosh et al., 2020) 
The TTF model links the task requirements, individual abilities, and the 
functionality of technology (Goodhue & Thompson, 1995). TTF theory focuses on the 
application and the general reliance on technologies and does not recommend any task or 
technology pairings that could produce a strong effect (Howard & Rose, 2019). The 
participants explained that the manual redundant tasks were identified first and then the 
automation solution that matched the tasks and the constraints was selected to ensure that 
the automation initiative was a success. Therefore, the TTF conceptual framework 
provided the correct lens for exploring strategies used by the PV systems managers to 
successfully automate AE case processing. 
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Theme 2: Business Operational Model Changes 
The second key theme that emerged from the data was business operational model 
changes. This theme referred to the outcome of implementing the automation solution. 
Initial analysis of the word cloud created by ATLAS.ti included AEs also called cases, 
system, automation, change, implementation, and automatically as the key words as 
shown in Figure 6. 
 
Figure 6. Word cloud for business operational model changes in the interview data. 
Created from ATLAS.ti. 
Business operational model changes theme included the following two strategies:  
Simplified, standardized, and efficient business processes by supplementing 
and reducing operational workforce. All participants stated that the introduction of the 
automation solution simplified and standardized the business processes and assisted in 
building efficiencies, as intended. P1 and P2 noted that although reduction of workforce 
was not the primary intention, the managers were able to successfully supplement the 
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manual, redundant tasks like double data entry to free up and repurpose the workforce to 
focus on more value-added tasks. P4 indicated that the PV operations team could reduce 
the number of full-time employees. 
Changes to organizational structure and job profiles. The introduction of 
automation solution led to changes in the way the AE case processing employees 
performed their jobs. P1 indicated that the AE case processor now only has to read the 
data on the screen as opposed to having to type or enter it manually. P2 and P3 noted that 
the mailbox that had to be monitored for new AEs need not be monitored because the 
AEs were automatically created in the database and the task was eliminated.  
Review of the documents provided by the participants showed process 
improvements and elimination of nonvalue-added activities as key objectives for 
automation. One of the challenges that the PV organization targeted to resolve was 
manual, time consuming, and inefficient processes. Ever increasing AE case volume, 
derivative operational cost, and resources were the other key challenges that the PV 
leadership decided to mitigate.  
The findings for business operational model changes matched previous studies in 
this regard. Stergiopoulos et al. (2019) noted that all PV leaders believed implementing 
AI-based solutions will decrease costs for PV operations including simplifying AE 
detection and processing. Mishra et al. (2019) summarized that business process 
simplification, standardization, and re-engineering are the critical factors for a successful 
automation strategy. Routray et al. (2020) confirmed that human intervention and review 
of AE seriousness will be required, and that automation can augment human review by 
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increasing efficiencies and consistency, thereby enabling reporting compliance. Beninger 
(2018) emphasized on the new skillsets, which will define the roles of the next generation 
of professionals who perform PV activities. Tomita (2019) added that organizations must 
expect to supplement the human workforce with expert systems.  
The TTF model matches the tasks as the events occur with the ability of a 
technology to address these events. TTF focuses on the application of technology 
(Howard & Rose, 2019). As concluded by Wang et al. (2020), the results of this study 
indicated that the automation technology implementation resulted in business process re-
engineering. The results also indicated that if the automation solution fits the business 
processes to successfully complete the tasks and enables employees’ personal fulfillment 
(Wang et al., 2020), then the managers can expect enhanced adoption of the technologies 
from the employees and a favorable attitude toward their jobs. 
Theme 3: Communication and Training Strategies 
The third key theme that emerged from the data was communication and training 
strategies. This theme included change management-related strategies. Initial analysis of 
the word cloud created by ATLAS.ti included communication, vendor, training, project, 




Figure 7. Word cloud for communication and training strategies in the interview data. 
Created from ATLAS.ti. 
Effective communication and training strategies played a key role in successful 
change management and adoption of the innovative technology solution within the PV 
organization. Communication and training strategies theme included the following two 
strategies: 
Open communication, collaboration, and engagement with stakeholders 
including end users and the vendor. Considering the high priority and ranking of the 
AE automation project, the project team maintained open communication and 
collaboration channels to ensure all the relevant stakeholders stayed engaged throughout 
the implementation. All participants indicated that communication was key and that 
introducing automation was viewed as a welcome change for the AE processing 
operational activities. P2 noted that the end users were made an integral part of the 
project, which made change management effortless. Managing the vendor using open 
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communication and collaboration was critical. Multiple touch points like steering 
committee and core team meetings were built to ensure the information is flowing 
through the organization and timely escalation and resolution of issues. P1 and P2 also 
indicated collaborating externally with other companies to explore the opportunities for 
automation, which can be practically implemented. 
Training. Since the introduction of automation changed the way certain business 
processes were managed, training was a critical aspect. The participants noted that 
multiple cycles of training were provided to the end users and the impacted third-party 
call center vendor. P2 and P3 explained that the end users were engaged in the 
implementation project and were trained multiple times. 
Review of the documents shared by the participants revealed that open 
communication and collaboration were key to set up an optimum governance structure 
during implementation. Lack of efficient collaboration tools was a key challenge in the 
initial stages of the project. Considering varied stakeholders, both internal and external, 
and the vendor implementation team located remotely added to the communication 
challenges. The team used online collaboration tools like Google and Smart Sheets to 
help track tasks and keep the teams aligned.  
Findings regarding communication and training strategies matched previous 
studies. Training and re-learning initiatives assist in preparing and guiding the in-house 
staff for digital transformation (Mishra et al., 2019). The human and technology 
relationship should also include user training, interaction, and collaboration sub-goals in 
order to be effective (Oyekan et al., 2017). PV systems managers realized the importance 
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of communication and collaboration early during the implementation project and ensured 
adequate measures were included to create open communication channels assisting in 
timely escalations and change management. Ghosh et al (2020) also recommended 
collaboration across the pharmaceutical industry between regulators and companies to 
build a generic process flow to fuel third-party innovations.  
In the TTF model, Goodhue and Thompson (1995) linked the technology solution 
with individual performance. Wang et al. (2020) used the user task technology fit model 
to summarize that the technology solutions alter business processes and existing work 
patterns leading to re-training and re-learning, which could increase employees’ work-
related stress (Wang et al., 2020). The study results showed that engaging the users early 
during the technology implementation led to easier change management and enhanced 
adoption of the solution and possibly job satisfaction, since the solution was fit for 
purpose. 
I included the researcher biases and assumptions that I had identified during data 
analysis. My biases and assumptions were confirmed to be a practical reality. PV systems 
managers I interviewed confirmed that they made the decisions to identify and implement 
innovative technology solutions. Participant P1 confirmed that among the many strategies 
available the PV organization managers decided to pursue the few above mentioned 
strategies for successful implementation. All participants confirmed that PV business 
operational model had an impact of introducing automation. And finally, the participants 
confirmed that innovative automation technology was used by their organization to 
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automatically read and create database entries, thereby eliminating redundant manual 
tasks, improving efficiencies, and over a period, achieving cost savings at the same time.  
Applications to Professional Practice 
Processing of an AE is an expensive resource-intensive process, which includes 
high risk of errors and operational inefficiencies (Ghosh et al., 2020). A detailed review 
of literature concluded that innovative technology such as data mining, machine learning, 
AI, and robotics could result in new operating models for PV (Beninger & Ibara, 2016; 
Lai, 2017), improve efficiencies and reduce PV operations costs (Karimi et al., 2015; Lu, 
2009; Schmider et al., 2018), better allocation of resources, and improve patient 
outcomes (Lewis & McCallum, 2019). In this doctoral study, I explored the strategies 
that PV systems managers in the pharmaceutical industry use to implement innovative 
technology solutions to automate AE processing. 
The single case that I selected to study was the implementation of an innovative 
technology solution to automate AE processing. The organization had a larger vision to 
automate PV business operations and this project was a part of that vision. Leaders and 
managers in the PV function decided to partner with a vendor to source and implement 
the solution, having realized that the organization lacked the necessary expertise on the 
technology. Multiple internal drivers such as objectives, timelines, cost, and compliance 
shaped the strategies the PV systems managers used to execute the project. Considering 
this being their first automation solution, the team ensured that the solution is fit for 
purpose, both task (functionality) and technology (architecture) perspectives. Strong 
project leadership and steering committee were established for robust governance and 
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monitoring. The managers established an open communication, collaboration, and 
training model to engage with the relevant stakeholders across multiple functions within 
the organization and the vendor. Measures were established to capture metrics in terms of 
volume, time, and quality of the business AE processing tasks before and after 
automation. Regular project governance and monitoring measures ensured the automation 
solution was implemented on time. The metrics defined the successful outcome of this 
implementation.  
The results showed that implementing the automation solution impacted the PV 
business operational model in a favorable manner. Business processes are now more 
simplified, standardized, and efficient. The metrics revealed major savings in terms of 
time and effort, which led to reduction in operational workforce and better allocation of 
the resources. The organization has started reallocating the savings from the manual labor 
toward more value-added tasks. By successfully implementing the automation solution, 
the PV organization managers have started defining a sustainable model for PV business 
operations. Other pharmaceutical companies can use the strategies identified in this study 
to realize the benefits of implementing innovative automation technology solutions to 
build a resilient and sustainable PV business operations organization. 
Implications for Social Change 
The successful strategies identified in this study can be used by organizations to 
adopt a digitized PV future. The study findings show a positive outcome and realization 
of savings from PV business operations because of strategically implementing and 
embedding automation. PV leaders can redirect the savings from PV operations toward 
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investing in the actual PV tasks like benefit-risk assessments of products, thereby 
improving patient outcomes and making the products more efficacious and safer for 
human use.  
The challenges on the pharmaceutical industry’s perspective include the 
management of the high volume of AEs, globally diverse and changing regulations, 
complex and evolving systems, and sparse PV expertise and talent (Price, 2018). 
Automation technologies can detect, database, and report AEs quicker, and manage high 
volume of AEs, which can help in protecting patients from unnecessary harm. The 
implications for positive social change include the identification of strategies to assist in 
making pharmaceutical medicines safer for human consumption. The savings from PV 
operations could also be used to help or assist with community projects that could bring 
about social change. Companies can also use the savings to offer scholarships to students 
pursuing courses and majoring in PV, thereby contributing to increase PV expertise and 
talent. 
Recommendations for Action 
This study revealed multiple strategies used by PV managers to implement AE 
case processing automation solution. The three themes that emerged included automation 
solution selection and implementation strategies, business operational model changes, 
and communication and training strategies. The results revealed that the PV systems 
managers can follow their company’s internal processes for solution selection and 
implementation, while paying close attention to the strategies identified in this study. By 
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successfully implementing automation technology for AE case processing, PV managers 
can realize time and effort savings and improve efficiencies with PV operations. 
Other stakeholders in the pharmaceutical industry who could benefit from this 
study include PV organization leaders and PV system database vendors. PV organization 
leaders can include the strategies identified in this study as they start defining their PV 
automation vision and objectives. PV system database vendors can build automation 
solutions which fit the demand from the end users and build a mutually benefitting, 
strategic partnership with the pharmaceutical industry. The findings of this study could 
also provide valuable insights to researchers interested in further research in PV AE 
management automation. I will share the findings of this study with the research 
participants. Additionally, I will disseminate the results through scholarly journals. 
Recommendations for Further Research 
This qualitative study focused on a single case. I interviewed PV systems 
managers employed in one pharmaceutical company. This study can be extended in a 
future research to include additional perspectives like end user feedback and IT 
technology strategies. Due to the ever-increasing volume of AE cases to be detected, 
processed, and reported, more companies are building visions for digitalization and 
sustainability by incorporating more automation for their PV business operations and 
case management. This opens multiple avenues for future research. This study can be 
replicated with other study population to explore additional successful strategies. This 
study focused on successful strategies to implement automation and not on the actual 
automation solution that was implemented. A future study can delve deeper into the 
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technology that was used in addition to exploring successful implementation strategies.  
One of the participants stated that their implementation was a success and that many 
others are not. A future study can explore strategies that were unsuccessful, which can 
serve as learnings for other companies starting on this journey. 
Reflections 
I work in the pharmaceutical industry and have extensive experience with 
technology solutions and implementations. I selected this research topic based on an 
exploration project I conducted for the company I work for as the PV leaders were 
exploring the PV landscape with an automation lens. Since I was close to the topic, I had 
assumptions and preconceived thoughts regarding automation solution implementation 
strategies. Therefore, mitigating personal bias was crucial for my study. I made a list of 
my potential bias and included them during data analysis. The results showed that my 
biases and assumptions were practical realities.  
The doctoral study process seemed a daunting task when I started. Soon, I started 
enjoying the process of conceptualizing the research, conducting, and concluding it. I did 
not face any challenges with the selection of participants and interviewing them. The 
participants took pride in their successful implementation as they are seeing the benefits 
now. I conducted my doctoral study as the small-scale project in the DBA Qualitative 
Research process course. I could effectively use the learnings from the pilot run for my 
study.  
I decided to use innovative technology as a part of the study data analysis process. 
I used an application on my mobile phone for the initial transcript of the interviews. The 
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application audio recorded the interview and converted it into a transcript output, which 
saved many hours of transcribing effort. I proof-read the entire output, paraphrased as 
needed, and subjected it to member checking process for confirming accuracy.  
Conclusion 
Processing of an AE is an expensive resource-intensive process, which includes 
high risk of errors and operational inefficiencies (Ghosh et al., 2020). As deducted in 
multiple previous research, technology can accelerate efficiencies and can be used to 
identify and process AEs faster and contribute to reduction of costs (Beninger, 2018; 
Donzanti, 2018; Karimi et al., 2015; Kusch et al., 2020; Lewis & McCullum, 2019; 
Schmider et al., 2018; Stergiopoulos et al., 2019). Organizations must internalize 
digitalization and incorporate in the operations methodology and structure in order to 
select the most suitable technological solutions and reap the maximum benefits 
(Buyukozkan & Gocer, 2018). Many pharmaceutical organizations are experimenting, 
and some are implementing automation technology solutions for AE case processing.  
This study focused on one such company whose PV organization managers have 
implemented an automation solution for AE case processing. The results of the study are 
in line with previous research. By prudently executing automation solution selection and 
implementation strategies and establishing communication and training strategies, the 
organization is now benefitting from simplified and efficient AE case processing business 
operations. Multiple factors such as internal drivers like cost and timelines, functionality 
of the automation solution, strong project leadership, stakeholder partnerships and 
engagement, including the size of the organization play an important role in shaping the 
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outcome of the digitalization initiative. With careful planning and execution, intelligent 
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Appendix A: Interview Protocol 
Interview introduction: 
1. Introduce the topic and objectives. 
2. Explain the purpose and scope of the study. 
3. Assure participants that their name and organization information will be 
kept confidential. 
4. Ask to record the interview and let the participant know that the materials 
will be stored for a maximum of 5 years. 




Reminders to do during 
the interview: 
Watch for nonverbal cues. 
Paraphrase as needed. 
Ask follow-up probing 
questions to get more in-
depth, rich data. 
 
 
1. What strategies did you use to identify automation 
solutions for AE case processing?   
2. What strategies did you use for implementing the 
identified automation solution?  
3. What, if any, kinds of operational changes did the 
automation solution require to your PV business 
operations model? 
4. What communication strategies were used to 
manage regulatory obligations and employee’s 
expectations to enable employee’s adoption of the 
automation solution? 
5. What key difficulties did your organization face 




6. How did your organization overcome the key 
difficulties to implementing automation technology 
solution? 
7. How did your organization assess the 
implementation strategies’ effectiveness? 
8. What additional information can you add about the 
development and implementation of the strategies 
your organization used for automating AE case 
processing? 
 
Wrap up interview Thank the participant for their time and information.  




Reminders to do during 
the interview: 
Watch for nonverbal cues. 
Paraphrase as needed. 
Ask follow-up probing 
questions to get more in-
Introduction:  
1. Reiterate and refresh the topic and objectives. 
2. Introduction for follow-up. 
3. Assure participants that their name and organization 
information will be kept confidential. 
4. Ask to record the follow-up interview. 
5. Let participants know they can stop if they do not 




depth, rich data. 
 
1. Share a copy of the interpretation and synthesis of 
answers for each question. 
2. Walk through each question including the 
interpretation of answers to ensure information was 
not missed and include any additional information. 
3. Ask any additional questions related to the initial 
interview to add clarity to the research topic. 
4. Wrap up follow-up interview by thanking the 
participant. 
 
 
 
